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1  ZUSAMMENFASSUNG 
Das Kaposi Sarkom assozierte Herpesvirus (KSHV) oder humanes Herpesvirus 8 
(HHV-8) ist das zuletzt entdeckte humane Herpesvirus. Es gilt als das infektiöse 
Agens des Kaposi Sarkoms (KS), des Primary Effusion Lymphoms (PEL) und der 
Multicentric Castleman’s Disease (MCD). 
Ähnlich wie andere Spezies der Familie der Herpesviren kodiert es für die 
vergleichsweise hohe Zahl von mindestens 89 viralen Proteinen. Die meisten von 
ihnen wurden bisher nicht näher funktionell charakterisiert. Um nähere Informationen 
über die Funktion dieser Proteine zu erhalten, wurde im Rahmen dieser Studie eine 
genomweite Analyse von viralen Protein-Protein-Interaktionen durchgeführt. Zu 
diesem Zweck wurden alle KSHV „open reading frames“ kloniert und in einer Yeast 
two-hybrid (Y2H) Matrix Analyse auf Protein-Protein Interaktionen gescreent. In 
diesen Screen wurden sowohl komplette Proteine als auch Protein-Fragmente 
eingefügt, so dass insgesamt mehr als 12.000 virale Protein-Interaktionen getestet 
und letztlich 125 Protein-Interaktionen identifiziert werden konnten (71 % der bisher 
bekannten intraviralen Protein-Interaktionen konnten in dieser Studie ebenfalls 
nachgewiesen werden). 
Um die Ergebnisse aus dem Y2H-Screen abzusichern und um ein Set von „high-
confidence“-Interaktionen zu generieren, wurden alle positiven Y2H-Interaktionen 
erneut duch Co-Immunoprezipitationen (Co-IP) getestet. Auf diese Weise konnten 
zirka 50 % der Interaktionen bestätigt werden. 
Die erweiterte bioinformatische Analyse des viralen Protein-Interaktionsnetzwerkes 
zeigte deutliche Unterschiede zu zellulären Netzwerken auf. 
Diese Studie bietet zudem eine Vielzahl neuer biologischer Ansätze an, welche es 
künftig noch im Detail zu untersuchen gilt. 
Weiter könnten diese Untersuchungsergebnisse zu einem vertieften Verständnis der 
viralen Pathogenese und möglicherweise zu neuen Ansatzpunkten für therapeutische 
Strategien führen. 
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1  SUMMARY 
Kaposi’s Sarcoma Associated Herpesvirus (KSHV) or Human Herpesvirus 8 (HHV-8), 
which represents the most recently identified human herpesvirus, is considered to be 
the etiological infectious agent of Kaposi’s sarcoma (KS), primary effusion lymphoma 
(PEL) and multicentric Castleman’s disease (MCD).  
Similarly to other species of the herpesvirus family, it encodes a rather large number 
of at least 89 viral proteins, most of which are not functionally characterized. In order 
to get some hints to the functions of these proteins, the goal of this study was a 
genome-wide analysis of viral protein-protein interactions. For this purpose, all KSHV 
open reading frames (ORFs) were cloned and screened for protein-protein 
interactions in a yeast two-hybrid matrix analysis. In this screen, in which more than 
12,000 viral protein interactions involving both full-length proteins and protein 
fragments were tested, 125 interacting protein pairs were identified (71% of the small 
number of intraviral protein interactions reported for KSHV were captured). To confirm 
the quality of the Y2H results and generate a set of high-confidence interactions, all 
positive Y2H interactions were retested by coimmunoprecipitation (CoIP) and 
approximately 50% could be confirmed. The extended bioinformatical analysis of the 
resulting viral protein interaction network including published sequence, functional 
and expression profiling data revealed marked differences to cellular networks. This 
study evokes a plethora of novel biological hypotheses which remain to be 
investigated in detail. It may also lead to an improved understanding of viral 
pathogenesis and eventually initiate novel therapeutic strategies. 
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2  INTRODUCTION 
2.1  Herpesviridae 
Herpesviruses are widely spread throughout vertebrates. Presently, more than 100 
different herpesvirus species have been classified, including eight species isolated 
from man. A herpesvirus virion encompasses a linear double-stranded DNA, which is 
wrapped on a fibrillar spoole, the core. The core with the associated DNA is 
protected by a protein shell called capsid. Together, capsid and nucleic acid form the 
nucleocapsid. The capsid measures about 100 to 110 nm in diameter and is 
composed of proteins organized in subunits known as capsomers. One capsid 
consists of 162 capsomers (150 hexameric and 12 pentameric). They form the 
icosaedric structure of the viral capsid. The nucleocapsid is enclosed by the 
tegument, a globular material that is frequently asymmetrically distributed and may 
be variable in amount. The tegument consists of different proteins with varying 
function. Tegument and capsid are encased by the envelope, a lipoprotein bilayer 
that may contain material from the membrane of a host cell as well as that of viral 
origin. The virus obtains the lipid molecules from the cell membrane during the viral 
budding process.  
 
Figure 1: The herpesvirus particle 
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The virus replaces the proteins in the cell membrane with its own proteins, creating a 
hybrid structure of cell-derived lipids and virus-derived glycopproteins (spikes) 
(Figure 1). The size of herpesvirus genomes ranges from 125 000 bp (VZV) to 230 
000 bp (CMV) (Chee et al., 1990; Rawlinson et al., 1996), coding for 60 to >170 
genes. In all types of herpesviruses, one can find unique and multiple repeat 
sequences (terminal and internal). Depending on the number of these, genome size 
of various isolates of a particular virus can vary by up to 10 kbp. 
Replication of herpesviruses takes place inside the nucleus. Thus, herpesviruses can 
use both the host's transcription machinery and DNA repair enzymes to support a 
large genome with complex arrays of genes (e.g. DNA polymerase, helicase, 
primase). Genes of herpesviruses are not arranged in operons, and in most cases 
they have individual promoters. In this regard herpesvirus genes are similar to their 
eukaryotic hosts, but unlike eukaryotic genes, only view herpesvirus genes are 
spliced.  
 As a common feature, herpesviruses are not eliminated after acute infection, but 
rather persist life-long in their hosts by establishing a latent state. They can reactivate 
following cellular stress (immunosuppression, UV-light, hormones etc.). Latency 
involves stable maintenance of the viral genome in the nucleus with limited 
expression of a small subset of viral genes. 
The herpesvirus family is divided into three subfamilies: the Alphaherpesviridae, 
Betaherpesviridae, and Gammaherpesviridae. This division is based on biological 
properties of the different members of the herpesvirus family and not solely on their 
genetic structure (Roizman and Pellet, 2001). 
Important characteristics of Alphaherpesviridae are a variable host range, relatively 
short reproductive cycle, a rapid spread in culture, an efficient destruction of infected 
cells, and the capacity to establish latent infections primarily but not exclusively in 
sensory ganglia.  
Betaherpesviridae are characterized by a more restricted host range, a long 
reproductive cycle and a slow progress of infection. Infected cells are frequently 
enlarged (cytomegalia). The virus can be maintained in latent form in secretory 
glands, lymphoreticular cells, kidneys, and other tissues.  
The host range of Gammaherpesviridae is even more restricted. In vitro, all members 
of this family replicate in lymphoblastoid cells, and some also cause lytic infections in  
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some types of epitheloid and lymphoblastic cells. Viruses are specific for either T or B 
lymphocytes. The latent virus is frequently detected in lyphoid tissue. This subfamily 
contains two genera: Lymphocryptovirus (EBV) and Rhadinovirus (KSHV, HVS). 
(Table 1) 
Table 1: Human Herpesviruses 
Subfamily Genera Viruses Clinic 
HHV-1 (Herpes 
simplex virus 1) 
Gingivostomatitis, 
Conjunctivitis, 
Keratitis 
HHV-2 (Herpes 
simplex virus 2) 
Herpes genitalis, 
Herpes 
neonatorum, a.o. 
Alphaherpesviridae  
HHV-3 (Varicella-
zoster virus, VZV) 
Varicella, Herpes 
zoster 
HHV-5 (Human 
Cytomegalovirus) 
congenital 
infection, infection 
in immuno-
suppressed 
individuals 
HHV-6A and B 
(Human B cell 
lymphotrophic 
virus) 
Roseola infantum 
Betaherpesviridae 
 
 
HHV-7  no clear evidence 
for a direct 
involvement of 
HHV-7 in any 
human disease 
Lymphocryptovirus HHV-4 (Epstein-
Barr virus, EBV) 
infectious 
mononucleosis, 
Burkitt’s 
lymphoma, 
nasopharyngeal 
carcinoma and 
others 
Gammaherpesviridae 
Rhadinovirus HHV-8 (Kaposi’s 
sarcoma-
associated 
herpesvirus, 
KSHV) 
Kaposi’s 
sarcoma, 
primary effusion 
lymphoma (PEL), 
multicentric 
Castleman’s 
diseases (MCD) 
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2.2  The replication cycle of herpesviridae 
A herpesvirus infection starts with an interaction of viral envelope-associated 
glycoproteins with a cellular receptor (adsorption). This interaction results in a fusion 
of the envelope and cell membrane. Subsequently, the nucleocapsid is released into 
the cytoplasm, where it migrates to the nucleus. The core enters via a nuclear pore 
where the genome is circularized. Inside the nucleus transcription and replication 
takes place. The replicated viral DNA is transferred into capsids. Tegument and 
envelope are acquired as the virion buds out through the nuclear membrane or 
endoplasmic reticulum. Virions are transported to the cell membrane via the Golgi 
complex, and the host cell dies as mature virions are released (Figure 2).  
 
 
Figure 2: The herpesvirus replication cycle 
A.  Viral glycoproteins allow the virus to attach to and enter the cell.  The envelope and cell membrane 
fuse and the viral capsid is released into the cytoplasm.  B.  Viral DNA enters the nucleus and the 
capsid is discarded.  C.  Host enzymes catalyze the early transcription, and viral mRNA directs the 
production of viral enzymes.  D.  These enzymes facilitate the replication of viral DNA.  E.  Late 
transcription produces the mRNA encoding the production of glycoproteins and capsid elements.  F.  
The capsid components return to the nucleus and the DNA is packaged. G.  The glycoproteins fix 
themselves to the nuclear membrane and the DNA-filled capsid acquires this coat as it buds out of the 
nucleus.  H.  The virus is released from the cell by unknown mechanisms. (According to C. Fowler 
from Ackerman et al., 1998) 
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Viral genes are expressed in a specific order: immediate-early (IE) genes, which 
encode predominantly regulatory proteins, early genes (E), which mainly encode 
enzymes for replicating viral DNA, and late genes (L), which encode structural 
proteins (Honess et al., 1974). Viral DNA replication is the target for a number of 
successful anti-herpesvirus drugs (e.g. acyclovir, gancyclovir, etc).  
2.3  The Kaposi’s sarcoma-associated herpesvirus (KSHV) 
2.3.1  The Kaposi’s sarcoma (KS) 
Moritz Kaposi, a Hungarian dermatologist working in Vienna, first described KS 
lesions in 1872. He published a report portraying the cases of five men with 
‘idiopathic multiple pigmented sarcoma of the skin’ including a patient who had 
developed visceral disease in the lung and gastrointestinal tract. Two decades later, 
this ‘pigmented sarcoma’ was designated Kaposi’s sarcoma (KS) at the suggestion of 
another prominent dermatologist, Heinrich Köbner. It is now referred to as classic KS 
(Antman and Chang, 2000; Russo et al., 1996) 
Before the outbreak of the AIDS epidemic, Kaposi’s sarcoma remained a rare 
curiosity to cancer researchers, predominantly found in men of Mediterranean, 
Eastern European or Jewish heritage. With the onset of the AIDS epidemic, the 
Kaposi’s sarcoma became the most common malignancy seen in the setting of HIV 
infection (Ahmed et al., 2001). 
Kaposi’s sarcoma has four major clinical presentations: classical (chronic), endemic 
(lymphadenopathic; african), immunosuppression-associated (transplant) and 
epidemic (AIDS-associated KS). KSHV can be isolated from KS tissue biopsies of all 
four types. As mentioned, classic KS is mainly found in the lower extremities of 
elderly men. Most commonly, it runs a relatively benign, indolent course with slow 
enlargement. Up to one third of the patients with classic KS develop a second 
primary malignancy, mostly a non-Hodgkin’s lymphoma (Reynolds et al., 1965; Safai 
and Good, 1980a; Safai et al., 1980b). 
Lymphadenopathic KS is endemic in prepubescent African children (male/female 
ratio: 3:1). It occurs as localized or generalized lymphadenopathy. The disease 
frequently follows a fulminating course with visceral organ involvement and usually  
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minimal skin or mucous membrane involvement (Taylor, 1971; Templeton and 
Bhana, 1975). 
One to four percent of all renal transplant patients and a number of other organ 
allograft recipients receiving prednisone and azathioprine develop transplantation-
associated Kaposi’s sarcoma. The average time to develop KS after transplantation 
is approximately 16 months. The extent and progression of the disease correlates 
with the loss of cellular immunity of the patient. After reduction or changes of 
immunosuppressive therapy, KS tumors may regress, suggesting a modulation by 
the host immune system (Penn, 1978). Transplantation-associated KS often remains 
localized to the skin, but visceral organ involvement is possible. 
Due to the AIDS epidemic, the AIDS-associated KS is currently one of the most 
common cancers in sub-Saharan Africa. Worldwide, it is the fourth most common 
cancer caused by an infectious agent – after gastric cancer (Helicobacter pylori), 
cervical cancer (human papillomavirus) and liver cancer (hepatitis viruses). In 
contrast to classic KS, AIDS-associated KS is rather aggressive. It often involves skin 
and mucosal surfaces in visceral organs.  
AIDS patients often develop KS as an early sign of the disease. A continuing 
downtrend in the incidence of KS as an AIDS-defining illness is currently observed (in 
1981, 48% of all AIDS patients developed KS, compared to 12% today). This 
development is probably due to the introduction of highly active antiretroviral therapy 
(HAART), which may delay and reduce the risk of opportunistic infections (Flexner, 
1998; Palella, Jr. et al., 1998; Selik et al., 1987). 
The histopathology of all of its clinical subtypes of KS is similar. It is a multifocal 
neoplasm characterized by dark purple lesions, which contains multiple cell types 
with the dominant cell being the spindle cell, derived from endothelial origins (Boshoff 
et al., 1997). In addition, KS lesions contain numerous infiltrating inflammatory cells 
as well as a profusion of neovascular elements (Monini et al., 1999). Often large 
numbers of extravasated erythrocytes and abundant hemosiderin deposits can be 
detected. The lack of a histological obvious neoplastic cell suggests that the disease 
is not neoplastic per se, but rather a hyperproliferative and highly vascularised cell 
mass (Figure 3). 
The observation that KS is present mainly in gay men infected with HIV-1, and not in 
individuals, who have acquired HIV-1 through a blood transfusion or intravenous drug 
use, lead the pathologist Yuan Chang and the epidemiologist Patrick Moore to  
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search for an infectious agent in KS. In co-operation with their colleagues at 
Columbia University (New York), in 1994 they identified sequences of a new human 
herpesvirus, which they called KSHV, in an AIDS-KS lesion (Chang et al., 1994; 
Ensoli et al., 1989). 
Similar to EBV, its closest human relative, KSHV infects B lymphocytes and is 
associated with B-cell lymphomas. KSHV has also been isolated from primary 
effusion lymphoma (PEL) (Cesarman et al., 1995) and multicentric Castleman’s 
disease (MCD) (Soulier et al., 1995; Chee et al., 1990). 
 
Figure 3: A Kaposi’s sarcoma lesion. 
KS lesions show extended areas of brown-blue-red plain maculae and patches with hyperkeratosis 
and skin ulceration. 
2.3.2  The primary effusion lymphoma (PEL) 
PEL, or BCBL (body cavity-based lymphomas), is a rare, rapidly fatal, non-Hodgkin’s 
malignancy associated with KSHV infection. It is generally present as a pleural or 
pericardial effusion without a detectable mass or peripheral lymphoadenopathy. 
Alternatively, PEL can form a solid mass in the lymph nodes, in the lungs or in the 
gastrointestinal tract. PEL occurs predominantly in HIV seropositive individuals in 
advanced stages of immunosuppression, but it is also seen in HIV seronegative 
patients. Moreover, PEL cells are frequently co-infected with EBV and KSHV, 
although EBV negative and KSHV- positive PEL have also been described 
(Arvanitakis et al., 1996). 
2.3.3  The multicentric Castleman’s disease (MCD) 
In contrast to the benign, localized hyperplasia of lymphatic tissue, first described by 
Castleman, KSHV-associated multicentric Castleman's disease is a highly malignant  
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lymphoproliferative disease (Castleman et al., 1956; Oksenhendler et al., 1996). It is 
associated with cytokine dysregulation. In particular IL-6 and IL-10 are elevated 
(Ablashi et al. 439-64) and closely associated to the KSHV viral load (Oksenhendler 
et al., 2000). 
Half of the patients with MCD do also develop a Kaposi's sarcoma. 
KSHV can be detected in most HIV seropositive cases of MCD as well as in 
approximately 40% of HIV seronegative MCD cases. KSHV positive MCD cases are 
now recognized as a distinct subset of MCD termed plasmablastic MCD, which 
contains large plasmablastic cells harbouring KSHV (Dupin et al., 2000). Unlike PEL 
cells, co-infection by EBV has not been detected in MCD plasmablasts. 
2.3.4  The virus particle 
The morphological structure of KSHV is typical for a member of the herpesvirus 
family. The virion of KSHV is approximately 120 to 150 nm in diameter. The electron-
dense core is of toroidal shape with the DNA genome wound around a proteinaceous 
spindle (Renne et al., 1996a). 
The icosahedral capsid – consisting of 162 hexagonal capsomeres – surrounds the 
core. It spans about 125 nm in diameter (Wu et al., 2000). The capsid is surrounded 
by an amorphous proteinaceous tegument and a lipid bilayer envelope containing 
numerous glycoproteins (e.g., gB, gD, and gH). 
Capsids are composed of four structural proteins: the major capsid protein (MCP / 
ORF25) forming the hexameric and the pentameric capsomers. One molecule of 
ORF62 / TRI-1 and two molecules of ORF26 / TRI-2 compose the capsid floor. The 
small basic capsid protein (ORF65) is associated with the tip of pentons and hexons 
on the capsid surface (Nealon et al., 2001; Trus et al., 2001). With the exception of 
the small basic capsid protein, which lacks significant sequence homology to its 
structural counterparts from the other subfamilies, each of these proteins has 
significant amino-acid sequence homology to capsid proteins in alpha- and 
betaherpesviruses. Lytic replication of KSHV leads to the formation of at least three 
capsid species:  A, B, and C. A capsids are empty, B capsids consist of a fifth 
structural protein, ORF17.5. C capsids contain the viral genome. 
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2.3.5  The KSHV genome 
The KSHV genome encodes >89 open reading frames, many of which are conserved 
in most herpesviruses. A long unique region of 145 kb is flanked by two terminal 
repeats consisting of several 801 bp repeat subunits of high G-C content (85%) 
(Neipel et al., 1997a; Neipel et al., 1997b; Russo et al., 1996). All presently known 
ORFs are encoded within the long unique region (Figure 4). 
 
Figure 4: The 165-kb Kaposi’s sarcoma associated herpesvirus (KSHV) genome.  
The entire coding region is flanked by terminal-repeat sequences (hatched boxes). The genome 
encodes numerous proteins that are homologous to cell-signalling and regulatory-pathway proteins 
found in human cells (solid boxes) and that are unique to KSHV and related rhadinoviruses. The 
proteins encoded include viral complement-binding protein (vCBP), viral interleukin-6 (vIL-6), viral 
macrophage inflammatory protein type 1 (vMIPI) and type II (vMIPII), viral Bcl-2 (vBcl-2), viral 
interferon regulatory factor (vIRF), viral cyclin (vCYC), latency-associated nuclear antigen (LANA), 
viral adhesin (vADH), G-protein-coupled receptor (vGCR), dihydrofolate reductase (DHFR), 
thymidylate synthase (TS), thymidine kinase (TK), and ribonucleotide reductase (RR). Stippled boxes 
indicate regions that are homologous to those of other herpesviruses. T1.1 and T0.7 denote 
nonhomologous ORFs with undetermined activities. (according to Antman and Chang, New England 
Journal of Medicine, April 2000) 
 
 
The sequence analysis of the KSHV genome suggests that it is belonging to the 
genus Rhadinovirus. Members of this genus share a colinear genomic organisation 
with each other. The complete sequence of KSHV (GenBank accession numbers 
U75698 and U 93872) was provided by sequencing viral DNA of a PEL cell line and 
of KS biopsy specimens (Russo, 1996; Neipel, 1997). It revealed that several blocks 
of genes are conserved among gammaherpesviruses. These genes are predicted to 
encode viral replication and structural proteins. Genes that are conserved in all 
mammalian herpesviruses are taken together in a set of “ancient” genes (McGeoch 
and Davison, 1999; Simas and Efstathiou, 1998). The gene with the highest 
intervirus identity is the viral DNA polymerase (ORF9), others are the DNA helicase 
primase (ORF40, ORF41 and ORF44), the processivity factor (ORF 59), the 
thymidylate synthase (ORF70), and the thymidine kinase (ORF21). 
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Between the blocks of conserved genes, there are clusters of genes which are 
unique for KSHV. Among these unique KSHV genes are several homologues of 
cellular proteins, which seem to be involved in the control of cell proliferation. 
Unique genes are designated with the prefix “K” for KSHV and are numbered 
sequentially K1 to K15 (Russo et al., 1996). 
Although K8 and K13 were subsequently found to have homologues, and additional 
unique ORFs (K4.1, K4.2, K8.1, K10.1, K10.5, K10.7, K11.1 and K14.1) have since 
been included. 
Later on, more information regarding the gene expression of KSHV became available 
and additional gene products were detected. Among these rather new open reading 
frames are K8 (a bZIP protein), K8.1 (a glycoprotein) and K10.5 + K10.7 (latent 
nuclear antigen-2). These genes were not identified in the first sequence analysis of 
the KSHV genome because they are encoded by spliced mRNAs. 
Current results suggest that KSHV uses mRNA splicing more than any other 
herpesvirus. Up to 15 KSHV genes are regarded to be regulated by mRNA splicing. 
As another interesting feature many KSHV transcripts are polycistronic. One of these 
transcripts is ORF50 / Rta (replication and transcriptional activator) (Gradoville et al., 
2000; Lukac et al., 1998; Lukac et al., 1999; Sun et al., 1999). ORF 50 is tricistronic 
and also encodes the downstream genes K8/K-bZIP/RAP and K8.1 (Gruffat et al., 
1999; Lin et al., 1999; Lukac et al., 1998; Seaman et al., 1999; Sun et al., 1998; Sun 
et al., 1999; Zhu et al., 1999). 
A comparison of several recently isolated complete or partial KSHV sequences 
suggests that K1 and K15 of KSHV, located at the very left and the very right end of 
the KSHV genome, exhibit greater variability than other KSHV genes studied so far 
(Lagunoff and Ganem, 1997; Lee et al., 1998; Neipel et al., 1997a; Nicholas et al., 
1998; Russo et al., 1996). Based on the analysis of K1 and K15, five KSHV variants 
(groups A to E) have been identified. Whereas group B is dominant in Africa, groups 
D and E are confined to Pacific Island and Amerindian populations. In Europe and 
North America, groups A and C predominate (Schulz, 2000). 
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Figure 5: Phylogenetic tree  
The tree was constructed based on a comparison of the amino acid sequences of the major capsid 
protein gene. EBV denotes Epstein-Barr virus, EHV-2 equine herpesvirus type 2, HVS herpesvirus 
saimiri, HSV herpes simplex virus, HSV-1 herpes simplex virus type 1, HSV-2 herpes simplex virus 
type 2, EHV-1 equine herpesvirus type 1, PRV pseudorabies virus, VZV varicella-zoster virus, HCMV 
human cytomegalovirus, HHV-6 human herpesvirus 6, and HHV-7 human herpesvirus 7. (according to 
Moore et al., 1996) 
2.3.6  The life cycle of KSHV 
Analogous to other herpesviruses, KSHV can establish a latent or lytic replication. In 
both states a characteristical set of genes is expressed (Miller et al., 1996; Miller et 
al., 1997; Renne et al., 1996b; Staskus et al., 1997; Zhong et al., 1996). The 
classification of individual KSHV ORFs into latent and lytic allows prediction of 
potential roles of these genes in the pathogenesis of virus infection.  
The PEL cell lines BCBL, BCP-1, BC-3, and KS-1 (which are free of EBV, HIV and 
other herpesviruses) have shown to be very beneficial for studies of KSHV. These 
cells are latently infected with the virus and rarely produce many virus particles. But if 
they are chemically induced with phorbol myristate acetate (PMA) and butyrate, the 
virus switches from the latent program to an ordered cascade of lytic gene 
expression, leading to viral replication, virion production, cell lysis, and viral release 
(Renne et al., 1996b; Sarid et al., 1998; Zhong et al., 1996) 
KSHV, like other members of the gammaherpesvirus subfamily, latently infects B-
cells and endothelial cells. Infected cells maintain the virus throughout cellular 
replication and can immortalize the infected cells (Ganem, 1997). During latent 
infection, the virus exists as a multicopy circular episomal DNA in the nucleus 
expressing a subset of viral genes: vIRF1 (K9), vIRF2 (K11), vIRF3 (K10.7), vIRF4  
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(K10), kaposin (K12), Lana1 (ORF73), FLIP (K13), v-cyc (ORF72), LAMP (K15) 
(Boshoff et al., 1995). 
The majority or KSHV genes remain silent during latent infection. The first groups of 
genes expressed after the induction of lytic replication are typically regulators of gene 
expression including the immediate early transactivators ORF50 (Rta), K8 (Zta or K-
bZIP), and ORF57 (posttranscriptional regulator of gene expression). These are 
followed by the expression of sets of genes, involved in replication of the viral DNA 
(Jenner et al., 2001). The structural genes and those involved in viral expression and 
maturation are expressed later, generally 24 hours after infection. 
Patterns of gene expression were examined by two different kinds of genome-wide 
approaches. The first one compared the expression patterns of each viral ORF 
during normal culture of PELs (i.e. latency) to the response of each to TPA treatment 
and lytic viral induction (Sarid et al., 1998). Class I consisted of constitutively 
expressed genes, they are considered to be latent transcripts. Class II genes were 
defined as those that have shown some basal level of transcription that could be 
further induced by TPA treatment. These are mainly immediate-early, or early, viral 
transcripts. The third class of viral genes are only inducible by TPA. These genes 
typically encode late genes, which are associated with viral replication.  
More recent approaches are based on DNA microarrays which permit a simultaneous 
comparison of the transcription kinetics of virtually all KSHV genes (Dittmer, 2003; 
Jenner et al., 2001; Paulose-Murphy et al., 2001). 
2.4  The KSHV Y2H screen 
2.4.1  From sequencing to understanding  
Large-scale sequencing projects provide new insight into the function of viral proteins 
which have not been characterized before. The sequence alone sheds little or no 
light on their function. Thus the development of standardized functional assays has 
become necessary. Such approaches are referred to as ‘functional genomics’. One 
approach to investigate the properties of a genome is the systematic analysis of 
protein-protein interactions which are essential for the structural and functional 
organization of the cell. The most common system used for the identification of novel 
interactions is the yeast two-hybrid system. 
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Although complications from false negative and false positive results, protein-protein 
interactions derived from Y2H screens contribute to the understanding of molecular 
processes, for at least four reasons: first, the interaction of an unknown protein, with 
proteins of known function can lead to a tentative assignment of a function to the 
unknown protein. Second, multiple interactions between a set of proteins belonging 
to the same functional group can hint at molecular mechanisms. Third, interactions 
can also occur between orthologous proteins of related organisms. Such protein 
pairs have been termed ‘interlogs’. Fourth, starting from the interaction results, maps 
can be generated depicting complicated networks of proteins interacting with several 
other partners. 
Here, we report the examination of two-hybrid interactions in all possible pairwise 
combinations between proteins of KSHV. 
2.4.2  The yeast two-hybrid system 
The basic concept of the yeast two-hybrid system is to detect the interaction between 
two proteins via transcriptional activation of one or several reporter genes. A classical 
eukaryotic transcription activator contains a domain that specifically binds to DNA 
sequences (the binding domain, BD) and a domain that recruits the transcription 
machinery (the activation domain, AD). In the two-hybrid system, these two domains 
are both fused to a polypeptide, X and Y, respectively. The resulting fusion proteins 
are directed into the yeast nucleus. 
The reporter genes will only be transcribed if X and Y interact with each other (Figure 
6). 
 
Figure 6 Transcriptional activation by the Y2H system.  
(A) Normal transcription. (B) Y2H transcription (according to Jiang Long) 
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2.4.3  Libraires versus arrays 
The two-hybrid system was originally intended to detect interactions between 
characterized proteins (Fields and Song, 1989). Quickly, it became clear that the 
system could be used to identify new interactions when expression libraries were 
screened. This has typically been done by screening a protein of interest fused to the 
DNA-binding domain against cells expressing a random cDNA library of potential 
protein partners fused to the activation domain, and applying a genetic selection for 
interaction. Plasmid DNA is recovered from cells expressing interacting proteins, and 
their identities are determined by DNA sequencing. Potential interaction partners 
obtained are frequently retrieved as fragments, since AD-cDNA fusion libraries are 
generated by reverse transcription and therefore do not exclusively contain full-length 
ORFs. The AD-cDNA approach possesses the advantage of partially defining the 
region of the AD protein required for the interaction. 
An alternative two-hybrid ‘matrix’ approach is to test all possible pairwise protein 
combinations in order to identify interacting partners. A set consisting of defined 
ORFs is often referred to as an ‘array’ or, in case it deals with a whole genome, as an  
‘ORFeome’. These arrays are fused to BD as well as AD, BD fusions and AD fusions 
are transformed into yeast of opposite mating types (Mat a and Mat α, respectively). 
Each pairwise combination of BD and AD fusions is generated by mating and 
examined on the expression of reporter genes. 
Arrays have the advantage that many tests can be performed under identical 
conditions at the same time. The results of these colonies, expressing a defined pair 
of proteins, can be compared directly. In addition, since arrays allow the rapid 
identification of positive interactions by their position, it is not necessary to sequence 
them as in a library screen. 
We constructed a ‘KSHV-ORFeome’, consisting of all full length ORFs and several 
protein domains of KSHV. These ORFs are easily transferable to various vector 
types. Thus, the ORFeome is not only available to the yeast two-hybrid system, but 
also to studies on a variety of other topics including the expression of recombinant 
proteins. 
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2.4.4  Genome-wide yeast two-hybrid screens 
Genome-wide protein-protein analyses have been performed in few organisms, 
including yeast (Uetz et al., 2000), helicobacter pylori (Rain et al., 2001), C. elegans 
(Reboul et al., 2003) and D. melanogaster (Giot et al., 2003).  
Two papers describe large-scale approaches to detect protein-protein interactions in 
yeast using sets of predefined open reading frames. The ultimate aim was to test all 
possible combinations between annotated ORFs of Saccharomyces cerevisiae (i.e. 4 
x 107 combinations). In one case, PCR products were cloned into BD and AD 
vectors, transformed into BD and AD vectors and then transformed into yeast cells of 
the opposite mating type (Ito et al., 2000). In the second strategy, PCR products 
were co-transformed with linear plasmids into yeast cells and gap repair occurred in 
vivo (Uetz et al., 2000). Ultimately, yeast cells transformed with BD fusion plasmids 
or AD fusion plasmids were collected, stored and assayed individually or in pools. A 
common intrinsic limitation of this strategy is to test only full-length proteins that were 
predefined.  
In 2001, Rain and colleagues performed another large-scale screen on Heliobacter 
pylori (Rain et al., 2001). They assayed 261 H. pylori proteins against a library of 
genome-encoded polypeptides. Over 1200 interactions were identified, connecting 
46.6% of the proteome.  
An even more complex organism, which has been screened in various ways, is the 
nematode Caenorhabditis elegans. This model organism was analyzed by several 
groups using a combination of DNA microarray, yeast two-hybrid analysis, and RNA 
interference (RNAi).  
The first yeast two-hybrid assays, focused on defined biological processes in 
C.elegans. Walhout and colleagues studied the vulval development in C. elegans by 
using a small array of 29 proteins (Walhout et al., 2000).  
Other aspects studied in C.elegans by the yeast two-hybrid system were the 
DNA damage response (DDR) pathway (Boulton et al., 2002) and components of the 
26S proteasome (Davy et al., 2001). 
By now, Reboul and colleagues have generated a set of reference clones for 
most predicted ORFs in the C. elegans genome (Reboul et al., 2003). In this study, 
they also used Recombinatorial Cloning (GATEWAY), similar to the study presented 
here.  
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2.4.5  Yeast two-hybrid screens for viral protein interactions 
Surprisingly, few viral genomes have been studied systematically for protein 
interactions, although their small size makes them an ideal target for such 
approaches. The first organism screened was the T7 bacteriophage (Bartel et al., 
1996). A library of random T7 protein fragments against random libraries of T7 
activation domain fusions. Among the 55 phage proteins, the authors found 25 
interactions, including four that had been described previously. 
Several RNA viruses express a precursor polyprotein which is fractionized into a 
couple of mature viral proteins either autocatalytically or by cellular proteases. The 
translation of the precursor polyprotein and its cleavage is obligatory for correct 
folding and processing of the mature proteins. Individually expressed mature proteins 
may not be processed correctly (Flajolet et al., 2000). Thus, it is no surprise that 
testing such mature proteins for pairwise interactions has not been very successfully. 
Neither in hepatitis C virus (HCV), nor in wheat streak mosaic virus (WSMV) 
interactions between mature proteins have been detected by two-hybrid assays (Choi 
et al., 2000a; Flajolet et al., 2000). In contrast, testing of random fragments resulted 
in the detection of a number of interactions. Apart from incorrect processing, an 
alternative explanation for this phenomenon might be that only certain protein 
fragments can efficiently act in conjunction with a fused activation or binding domain. 
Therefore the interaction can only be detected if these fragments are used. In 
WSMV, which belongs to the filamentous potyvirus (+) strand RNA virus family, the 
polyprotein precursor is cleved into nine mature proteins. When Choi and colleagues 
tested the mature proteins by two-hybrid assays, they could not observe any 
heterologous interactions, but when random fragments were used, multiple 
interactions were detected: the proteins P1, HC-Pro, P3 and CI interacted with each 
other in all possible combinations. Interactions involving the P3 protein could only be 
detected in in vitro assays, but not in yeast. 
According observations have been made in HCV, a flavivirus (+) strand RNA virus: 
by testing full-length proteins in a two-hybrid assay no interactions could be detected 
(Flajolet et al., 2000). In contrast, by screening of random fragments five interactions 
were observed, such as the known interaction between the capsid homodimer and 
the protease dimer and between the nonstructural proteins NS3 and NS4a, as well 
as multiple novel interactions such as between NS2 and NS4a. 
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However, expression and processing of polyproteins is not necessary for all 
interactions to be detected among processed RNA virus proteins. In both pea seed-
borne mosaic virus (PsbMV) and potato virus A, which belong to the potyvirus (+) 
strand RNA virus family similar to WSMV (Guo et al., 2001), as well as in a subset of 
poliovirus proteins (Cuconati et al., 1998), interactions have been detected among 
cloned mature proteins. 
Recently, Fields and colleagues reported a protein-protein interaction screen of a 
member of the poxvirus family, which constitute the other known family of large DNA 
viruses. It is thus far the largest virus screen performed in a systematic way for 
protein interactions. This array screen was performed with 266 genes from vaccinia 
virus, The screen of about 70 000 protein pairs revealed only 37 protein-protein 
interactions of which 13 (35%) were self interactions (i.e. homodimers or 
homomultimers). Of the 24 remaining interactions, five (i.e., 13.5%) were detected in 
both orientations, i.e., with the two proteins as both bait and prey construct (McCraith 
et al., 2000). Thus two-hybrid screens should always include all possible 
combinations with every protein as bait and prey construct (for N proteins this 
requires N2 combinations and not just N2/2). Double-checking each pair not only 
confirms each combination but also avoids false negative interactions if one of the 
two partners is a transcriptional activator and therefore cannot be used as a bait. One 
of the reasons for the small number of interactions detected in vaccinia virus may be 
caused by the fact that vaccinia virus replication and transcription take place in the 
cytoplasm. This means, that viral splicing signals have not been eliminated in the 
course of evolution. If these sequences are expressed in the nucleus of eukaryotic 
cells from transfected plasmids, a considerable number of transcripts may be 
artificially spliced and the proteins encoded either disrupted or structurally altered. In 
fact, 282 putative introns were found in the Vaccinia genome. That is more than one 
putative intron per ORF (Uetz et al., 2004). Another disadvantage of the Vaccinia 
screen might be that transmembrane proteins were only expressed as full-length 
proteins. The two-hybrid system bases on an interaction of bait and prey fusion 
proteins in the nucleus, thus membrane-anchored may have contributed to the large 
number of interactions not detected in this study. 
However, protein-protein interaction maps have not been reported for any member of 
the herpesvirus family yet. Large DNA viruses contain approximately one order of 
magnitude fewer genes than eubacteria and are thus particularly well suited for  
Introduction 
 
  20
genome-wide analyses. Herpesviral replication, transcription, and capsid assembly 
occur in the nucleus, and herpesviral transcripts can be spliced similarly to host 
mRNAs.  
The limited number of genes makes it possible to combine the results of 
several genome-wide functional screens focusing on different aspects.  
Several protein interactions have been shown before for KSHV, for example the 
interaction between the two capsid proteins ORF25 and ORF65, as well as the 
protein interaction between the immediate early transcriptional activator ORF57 
(RTA) and ORF50. In addition, a reasonable number of protein interactions have 
been predicted, for example the interaction between different DNA packaging and 
tegument proteins. 
2.5  Topology of protein interaction networks 
2.5.1  Scale-free networks 
Complex networks are rarely connected randomly. Most complex networks fall under 
the category scale-free network. Scale-free networks are characterized by an uneven 
distribution of connectedness. Some nodes are “highly connected hubs”, but most 
nodes only have one or few interaction partners (Figure 7). 
 
 
Figure 7: Scale-free and random networks:  
Most complex networks, such as airline traffic routes, weblog links and terrorist networks are scale-
free networks, since few hubs are far more connected than other nodes. 
 
The term “scale-free” was established by Albert-Laszlo Barabasi and his colleagues 
(Barabasi and Albert, 1999). In 1999, they mapped the connectedness of the World 
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Wide Web and found that the the structure of the Web did not conform to the model 
of random connectivity, but that few nodes were far more connected than others. 
They found that scale-free networks follow a so-called power law distribution, what 
means that the probability P(k) that a node connects with k other nodes is 
proportional to k-y, what means that there is no specific number of links per node, but 
that there are many nodes with few links and some nodes with many interaction 
partners. Such highly connected nodes are called hubs. Scale-free networks have 
been used to explain networks as diverse as those of social networks, cancerous 
cells, the dispersal of sexually transmitted disease and protein interaction networks.  
A strength of scale-free networks is that a random node failure has very little effect 
on its connectivity or effectiveness, while in random networks a small number of 
random failures can collapse the network.  
The weakness of scale-free networks is that they fail, when they stand under 
intentional attack on their hubs. If a certain number of the hubs are eliminated 
simultaneously, the network will collapse. Simultaneity of the attacks is important, 
because scale-free networks are able to heal themselves rapidly if only an insufficient 
number of hubs are removed.  
Cellular protein interaction networks exist for several model organisms. It has been 
found that their degree distribution follows a power-law decay and they exhibit thus 
scale-free properties. Here, we establish the first viral protein network and examine 
topology and behaviour in comparison to known cellular networks 
2.5.2  The small world phenomenon 
The expression “small world phenomenon” was originally coined by Stanley Milgram, 
a sociologist, who published in 1967 the hypothesis that two random US citizens 
were connected by an average of six acquaintances (Milgram, 1967). The concept 
gave rise to the famous phrase “six degrees of separation”. Although there was some 
doubt to whether the "whole world" was a small world, it became matter of fact that 
there is a large number of small worlds within most complex networks.  
Since then, a number of studies have dealed with the problem more analytically. 
Watts and Strongatz formulated the expression “small world networks” by analogy 
with Milgram’s “small world phenomenon” (Watts and Strongatz, 1998). They 
provided evidence that small-world properties are arising in a multitude of physical 
and biological networks. 
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Small-world networks can be found at the boundary between regular networks, like 
lattices, and random networks. A small-world network can be created out of a regular 
network by rewiring of a few short cuts.  
Small world networks are characterized by a short average path length or distance 
between two nodes (also named the diameter of a network). The distance between 
two nodes is defined as the number of edges along the shortest pathway connecting 
them. 
Another typical property of these networks is their high clustering coefficient. High 
clustering implies that, if a node A is linked to node B, and B is linked to node C, 
there is an increased probability that A will also be linked to C. In contrast, linking 
with a distant node is relatively rare. We distinguish between a local and a global 
“clustering coefficient”. The local clustering-coefficient C measures to how many links 
one node is connected, in comparison to the maximal number of connections. It is 1 if 
the node is connected to all neighbors and 0, if it is not connected. 
The global clustering coefficient measures the linking of a whole network. It is 
1, if each node is connected to every other node.  
All known cellular protein interaction networks display small-world properties. 
In this work the characteristics of a viral network have been examined. 
2.6  Aims of this project 
Herpesviruses possess a large double-stranded DNA genome encoding 
approximately 80 to 160 viral proteins. The function of the majority of viral proteins is 
currently not or only poorly understood. In particular, very little is known about how 
these proteins interact and are attuned to each other. The aims of this study were (i) 
to generate a set of plasmids representing the KSHV ORFeome by recombinatorial 
cloning, (ii) to perform a yeast two-hybrid matrix screen (iii) iv) to verify positive Y2H 
interactions by co-immunoprecipitation and (iv) to perform a bioinformatical analysis 
of the results received. 
. 
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3  MATERIAL AND METHODS 
3.1  Materials 
3.1.1  Equipment 
Bacterial Shaker      Kühner, Bürsfelden, Switzerland 
Balances       Sartorius, Göttingen, Germany 
Centrifuge GP      Beckman, Palo Alto, USA 
Centrifuge J2-21      Beckman, Palo Alto, USA 
Centrifuge Varifuge 3.0R     Heraeus, Hanau, Germany 
Centrifuge Minifuge RF     Heraeus, Hanau, Germany 
Centrifuge Labofuge T     Heraeus, Hanau, Germany 
Centrifuge, refrigerated and non-refrigerated  Heraeus, Hanau, Germany 
Eagle Eye   Stratagene, Amsterdam, The 
Netherlands 
Film Developing Machine  Optimax Typ TR MS Laborgeräte, 
Heidelberg, Germany 
Fluorescence/light Microscope Axiovert 35  Zeiss, Oberkochen, Germany 
Fluorescence/light Microscope Axiovert 200M  Zeiss, Oberkochen, Germany 
Fridge (4°C)       Liebherr, Ochsenhausen, Germany 
Freezer (-20°C)      Liebherr, Ochsenhausen, Germany 
Freezer (-80°C)  Forma Scientific, Inc., Marietta, Ohio, 
USA 
Cryo 1°C Freezing Container    Nalgene Nunc, Wiesbaden, Germany 
Gel Dryer       Bio-Rad, Munich, Germany 
GelAir Drying System     Bio-Rad, Munich, Germany 
Incubators for Cell Culture (37°C)  Forma Scientific, Inc., Marietta, Ohio, 
USA 
Inverted Microscope TMS     Nikon, Düsseldorf, Germany 
Laminar Flow Hood Steril Gard II A/B3  The Baker Company, Sanford, 
Maine,USA  
Magnetic Stirrer with heating block   Janke & Kunkel, Staufen, Germany 
Microwave       AEG, Berlin, Germany 
Material and Methods 
 
  24
PCR Thermal Cycler GeneAmp 2400   Perkin Elmer, Weiterstadt, Germany 
pH-Meter       WTW, Weilheim, Germany 
Photometer Gene Quant II    Pharmacia/LKB, Freiburg, Germany 
Pipettes       Gilson, Villies Le Bel, France; 
EppendORF, Hamburg, Germany 
Pipetting Aid      Technomara, Zürich, Switzerland 
Electrophoresis Power supply EPS200  Amersham-Pharmacia, Freiburg, 
Germany 
Overhead Mixer      Heidolph, Schwabach, Germany 
384-Pin Replicator     Nalge Nunc International 
Robotic Workstation    Biomek 2000, Beckman Coulter 
Sonifier 450  Branson Ultrasonics Corp., Danbury, 
USA 
Thermomixer      Eppendorf, Hamburg, Germany 
UV-Transilluminator (366 nm)    Vetter, Wiesloch, Germany 
   (254 nm)    Konrad Benda, Wiesloch, Germany 
Vortex Mixer      IKA Works, Inc, Wirmington, USA 
Water Bath       Julabo, Seelbach, Germany 
       GFL, Burgwedel, Germany 
3.1.2  Chemicals 
Acetic Acid       Roth, Karlsruhe, Germany 
Acrylamide/Bisacrylamide 37,5/1   Roth, Karlsruhe, Germany 
(Rotiphorese Gel 30)   
Agar for plates      Gibco BRL, Karlsruhe, Germany 
Agarose Electrophoresis Grade   Invitrogen, Karlsruhe, Germany 
Ammonium Persulfate (APS)    Sigma, Munich, Germany 
Ampicillin  Roche Diagnostics, Mannheim, 
Germany 
Bacto Peptone     BD Biosciences Clontech, Heidelberg, 
Germany 
Bacto Tryptone     BD Biosciences Clontech, Heidelberg, 
Germany 
Bacto Yeast Extract   BD Biosciences Clontech, Heidelberg, 
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Germany 
Bicine       Sigma, Munich, Germany 
Bromophenol Blue      Serva, Heidelberg, Germany 
BSA (Bovine Serum Albumin)    Sigma, Munich, Germany 
Calcium Chloride      Merck, Darmstadt, Germany 
Chloramphenicole      Sigma, Munich, Germany 
Coomassie Brilliant Blue R-250   Bio-Rad, Munich, Germany 
Dextrose       BD Biosciences Clontech, Heidelberg, 
Germany 
Dimethylsulfoxid (DMSO)     Merck, Darmstadt, Germany 
Dithiothreitol (DTT)      Roth, Karlsruhe, Germany 
dNTPs  Roche Diagnostics, Mannheim, 
Germany 
Dulbecco’s modified Eagle’s medium (DMEM) Gibco BRL, Karlsruhe, Germany 
Ethanol (EtOH)      Riedel-de Haën, Seelze, Germany 
Ethidium Bromide      Sigma, Munich, Germany 
Ethylendiamintetraacetate Disodium Salt  Roth, Karlsruhe, Germany 
(EDTA) 
Ethylene Glycol      Sigma, Munich, Germany 
Fetal Calf Serum (FCS)    Gibco BRL, Karlsruhe, Germany 
Gentamycin      Serva, Heidelberg, Germany 
Glucose      Merck, Darmstadt, Germany 
Glutathione-Sepharose 4B    Amersham-Pharmacia, Freiburg, 
Germany 
Glycerol       Roth, Karlsruhe, Germany 
Glycine       Serva, Heidelberg, Germany 
Histogel      Linaris, Wertheim-Bettingen, Germany 
Hydrochloric Acid (HCl)     Merck, Darmstadt, Germany 
Imidazole       Fluka, Seelze, Germany 
Isopropanol       Riedel-de Haën, Seelze, Germany 
Isopropylthio-b-D-galactosid (IPTG)   Roth, Karlsruhe, Germany 
Kanamycin       Serva, Heidelberg, Germany 
L-Glutamine       Gibco BRL, Karlsruhe, Germany 
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L-Glutathione (reduced)     Merck, Darmstadt, Germany 
L-Glutathione (oxidized)     Fluka, Seelze, Germany 
Magnesium Chloride     Merck, Darmstadt, Germany 
Magnesium Sulfate     Merck, Darmstadt, Germany 
2-Mercaptoethanol      Merck, Darmstadt, Germany 
Methanol       Merck, Darmstadt, Germany 
Nonidet P40 (NP-40)     Fluka, Seelze, Germany  
Pefabloc  Roche Diagnostics, Mannheim, 
Germany 
Polyethylene Glycol (PEG 1000)   Sigma, Munich, Germany 
Penicillin-Streptomycin     Gibco BRL, Karlsruhe, Germany 
Phenylmethylsulfonfluoride (PMSF)  Roche Diagnostics, Mannheim, 
Germany 
Phosphate Buffered Saline (PBS)  Dulbecco’s Gibco BRL, Karlsruhe, 
Germany 
Ponceau S       Sigma, Munich, Germany 
Potassium Acetate      Riedel-de Haën, Seelze, Germany 
Potassium Chloride     Merck, Darmstadt, Germany 
Potassium Phosphate Salts    Merck, Darmstadt, Germany 
Protein G Sepharose Fast Flow  Amersham-Pharmacia, Freiburg, 
Germany 
RPMI (Rosswell Park Memorial Institute)1640 Gibco BRL, Karlsruhe, Germany 
SD Base Medium      BD Biosciences Clontech, Heidelberg, 
Germany     
Skim Milk Powder      Merck, Darmstadt, Germany 
Sodium Acetate      Riedel-de Haën, Seelze, Germany 
Sodium Azide      Serva, Heidelberg, Germany 
Sodium Borate      Merck, Darmstadt, Germany 
Sodium Chloride      Riedel-de Haën, Seelze, Germany 
Sodium Thiosulfate     Merck, Darmstadt, Germany 
Sodium Codecylsulfat (SDS)    Merck, Darmstadt, Germany 
Sodium Carbonate      Merck, Darmstadt, Germany 
Sodium Hydroxid      J.T.Baker B.V., Deventer, Holland 
Sodium Phospate salts     Merck, Darmstadt, Germany 
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Tetramethylethylendiamin (TEMED)  Amersham-Pharmacia, Freiburg, Germany 
12-O-tetradecanoylphorbol-13-acetate (TPA)  Sigma, Munich, Germany 
Tris(hydroxymethyl)aminomethan (Tris)  Roth, Karlsruhe, Germany 
 
Triton X-100       Serva, Heidelberg, Germany 
Trypsin       Gibco BRL, Karlsruhe, Germany 
Tween 20       Merck, Darmstadt, Germany 
Urea        Roth, Karlsruhe, Germany 
3.1.3  Additional materials 
Autoradiography Films BIOMAX-MR   Eastman-Kodak, Rochester, USA 
Cell Culture Plastic Ware     Greiner, Nürtingen, Germany 
Nunc, Wiesbaden, Germany 
Falcon/Becton Dickinson, Heidelberg, 
Germany 
Filter Paper (3 mm)     Whatman Ltd., Maidstone, England 
Glass Slides for IF  Marienfeld, Bad Mergentheim, 
Germany 
Protran Nitrocellulose Transfer Membranes  Schleicher & Schuell, Dassel, 
Germany 
Sterile Filter Units      Millipore 
Single-well Microtiter Plates   Omnitray; Nalge Nunc International 
3.1.4  Cell lines 
293    human embryonal kidney cell line (ATCC: CRL-1573) 
HeLa     human cervix carcinoma (ATCC :CCL-2) 
BCBL-1 body cavity-based lymphoma cell line, kindly provided by 
Dr. Don Ganem, USCF, San Francisco, USA  
3.1.5  Recombinant vaccinia viruses 
Recombinant vaccinia virus vTF-7 expressing T7 polymerase was provided by the 
NIH AIDS reagent program (Fuerst et al., 1986).  
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3.1.6  Bacterial strains 
DH5a     Invitrogen, Karlsruhe, Germany 
Genotype: F− 80dlacZΔM15 endA1 recA1 hsdR17 (rk− mk+) supE44 
thi-1 λ− gyrA96 relA1 Δ(lacIZYA-argF)U169  
     
DB3.1    Invitrogen, Karlsruhe, Germany  
Genotype: F−gyrA462 endA .(sr1-recA) mcrB mrr hsdS20 (r B - m B - 
) supE44 ara14 galK2 lacY1 proA2 rpsL20(Str R ) xyl5 
ë - leu mtl1 
  
DH10B   Invitrogen, Karlsruhe, Germany 
Genotype: F−mcrA Δ(mrr-hsdRMS-mcrBC) 80dlacZΔM15 ΔlacX74 
deoR recA1 araD139 Δ(ara leu)7697 galU galK rpsL 
endA1 nupG 
 
Top10: Invitrogen, Karlsruhe, Germany 
Genotype: F-, mcrA, Δ(mrr-hsdRMS-mcrBC), 80lacZΔM15ΔlacX74, 
deoR, recA1, araD139 D(ara-leu)7697, galK, rpsL(StrR), 
endA1, nupG . 
3.1.7  Yeast strains 
AH109   BD Biosciences Clontech, Heidelberg, Germany 
Genotype:  MAT a, trp1-901, leu2-3, 112, ura3-52, his 3-200, gal4Δ, 
LYS2 : : GAL1UAS-GAL1TATA-HIS3, GAL2 UAS-GAL2 TATA-
ADE2, URA3 : : MEL1 UAS-MEL1 TATA-lacZ 
 
Y187    BD Biosciences Clontech, Heidelberg, Germany 
Genotype:  MATα, ura3-52, his3-200, ade2-101, trp 1-901, leu2-3, 
112, gal4Δ, met-, gal 80Δ, URA3 : : GAL1UAS-GAL1TATA-
lacZ 
 (Harper et al., 1993) 
3.1.8  Plasmids  
pGADT7 (Apr)  BD Biosciences Clontech, Heidelberg, Germany  
pGBKT7 (Kmr)  BD Biosciences Clontech, Heidelberg, Germany 
pDONR207 (Gmr)  Invitrogen, Karlsruhe, Germany 
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Figure 8a: Map of the pGADT7 vector. 
pGADT7 consists of an ampicilin resistance gene for selection in E.coli and the LEU2 nutritional 
marker for selection in yeast. In yeast, pGADT7 expresses a protein of interest as a GAL4 activation 
domain (GAL4 AD) fusion. Transcription starts with the constitutive ADH1 promoter ( PADH1) and 
ends with the ADH1 termination signal ( TADH1). The GAL4 AD sequence includes the SV40 nuclear 
localization signal (SV40 NLS; 1) so that fusions translocate to the yeast nucleus. GAL4 AD fusions 
also contain a hemagglutinin (HA) epitope tag for identification with HA-Tag antibody. 
 
 
 
Figure 8b: Map of the pGBKT7 vector. 
GBKT7 carries a kanamycin resistance for selection in E. coli and the TRP1 nutritional marker for 
selection in yeast. The pGBKT7 vector expresses proteins fused to the GAL4 DNA binding domain 
(DNA-BD). In yeast, fusion proteins are expressed from the constitutive ADH1 promoter ( PADH1); 
transcription is terminated by the T7 and ADH1 transcription termination signals ( TT7 & ADH1). pGBKT7 
also contains the T7 promoter, a c-Myc epitope tag and the SV40 nuclear localization signal (SV40 
NLS) 
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The DNA-BD and AD fusion vectors pGBKT7 and pGADT7 express fusion proteins at 
high levels to make even weak and transient protein interactions detectable. pGADT7  
and pGBKT7 express different bacterial selection markers to simplify their 
independent isolation in E.coli. Bait and prey inserts are expressed as GAL 4 fusions 
with c-Myc and hemagglutinin (HA) tags, respectively. The epitope tags eliminate the 
need to generate specific antibodies for each new protein. The T7 promoter is 
included to facilitate in vitro transcription and translation of the epitope-tagged bait 
and prey proteins. The T7 promotor was also used as priming site for DNA 
sequencing. It can also be used to express the insert in mammalian cells expressing 
the T7 RNA polymerase, for example by infection with recombinant vaccinia virus. 
3.1.9  Oligonucleotides 
Genes that encode for glycoproteins were amplified in three versions: as a full length 
(FL) product, as cytoplasmatic (cyt/d2) and external (ext/d1) domain. For genes that 
undergo splicing events, BC-1 RNA or plasmid DNA was used as template.  
Table 2: KSHV ORFs and Oligonucleotides  
ORF Size Template   Primer- Sequence 
K1 (FL) 860 bp BC-1, gDNA * for AAAAAGCAGGCTCCGCCATGTTCCTGTATGTTGTCTGC 
      rev AGAAAGCTGGGTTCAGTACCAATCCACTGGTTGC 
K1 cyt 113 bp BC-1, gDNA  for AAAAAGCAGGCTCCGCCCATTGTCAAAAACAACGTGAC 
      rev AGAAAGCTGGGTTCAGTACCAATCCACTGGTTGC 
K1 ext 693 bp BC-1, gDNA  for AAAAAGCAGGCTCCGCCATGTTCCTGTATGTTGTCTGC 
      rev AGAAAGCTGGGTTATACAAGAAAATGCACTTCAAT 
ORF 4 1653 bp BCBL-1, gDNA * for GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATGGCCTTTTTAAGACAAAC
      rev GGGGACCACTTTGTACAAGAAAGCTGGGTGCTAACGAAAGAACAGATAG 
ORF 6 I 1800 bp BC-1, gDNA  for AAAAAGCAGGCTCCATGGCGCTAAAGGGACCAC 
      rev AGAAAGCTGGGTTAATGGACGGATTTGATGTTCTCTCTG 
ORF 7 2088 bp BCBL-1, gDNA  for AAAAAGCAGGCTCCGCCATGGCAAAGGAACTGGCGGCG 
      rev AGAAAGCTGGGTCTAGACCTGGGAGTCATTGTGG 
ORF 8 cyt 180 bp BAC ** for GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCCGCCGCACCAATACCATAGC
      rev GGGGACCACTTTGTACAAGAAAGCTGGGTGTCACTCCCCCGTTTCCGG 
ORF 9 3039 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCATGGATTTTTTCAATCCATTTATC 
      rev AGAAAGCTGGGTCTAGGGCGTGGGAAAAGTC 
ORF 10 1257 bp BAC for GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATGCAGACAGAGGCAACG 
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      rev GGGGACCACTTTGTACAAGAAAGCTGGGTGTCACGATTGCATGGGTTC 
ORF 11 1224 bp BAC for GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATGGCGCAGGAGTCAGAG 
      rev GGGGACCACTTTGTACAAGAAAGCTGGGTGCTAACTGCGTCCGGTGGC 
K 2 615 bp BAC for GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATGTGCTGGTTCAAGTTG 
      rev GGGGACCACTTTGTACAAGAAAGCTGGGTGTTACTTATCGTGGACGTC 
ORF 02 633 bp BAC for GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATGGATCCTACACTTTAC 
      rev GGGGACCACTTTGTACAAGAAAGCTGGGTGTTACGAAGTCTCACTGAAG 
K3 (FL) 1002 bp BAC for GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATGGAAGATGAGGATGTTC 
      rev GGGGACCACTTTGTACAAGAAAGCTGGGTGTTAATGAAACATAAGGGC 
K3c1 246 bp JSC-1, gDNA * for GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCATGGAAGATGAGGATGTTC 
      rev AGAAAGCTGGGTTATTCCAGACCCTCCTGGTAAG 
K3c2 575 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCCACATGATGCGCCACGTGGGG 
      rev GGGGACCACTTTGTACAAGAAAGCTGGGTGTTAATGAAACATAAGGGC 
ORF 70 1014 bp BAC for AAAAAGCAGGCTATGTTTCCGTTTGTACCTTTAAG 
      rev AGAAAGCTGGGTCTATACTGCCATTTCCATAC 
K 4 285 bp BAC for AAAAAGCAGGCTATGGACACCAAGGGCATC 
      rev AGAAAGCTGGGTTCAGCGAGCAGTGACTGG 
K 4.1 345 bp BAC for AAAAAGCAGGCTATGTGGAGCATGTGCTGG 
      rev AGAAAGCTGGGTCTAGGGGCATAACCCTTTAC 
K 4.2 550 bp BAC for AAAAAGCAGGCTATGCAAATTAGCAAAGCC 
      rev AGAAAGCTGGGTTTATTGAAGCCCAGGCGAC 
K5 (FL) 771 bp BCBL-1, gDNA for AAAAAGCAGGCTATGGCGTCTAAGGACGTAG 
      rev AGAAAGCTGGGTTCAACCGTTGTTTTTTGG 
K5c1 259 bp BC-1, gDNA for AAAAAGCAGGCTATGGCGTCTAAGGACGTAG 
      rev AGAAAGCTGGGTTATTCAAAAATTTCTTGGCGCTCC 
K5c2 344 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCGGCGGCATATGCCGCGTAAGTGG 
      rev AGAAAGCTGGGTTCAACCGTTGTTTTTTGG 
K 6 288 bp BAC for AAAAAGCAGGCTATGGCCCCCGTCCACGTTTTATG 
      rev AGAAAGCTGGGTCTAAGCTATGGCAGGCAG 
K 7 381 bp BAC for AAAAAGCAGGCTATGGGAACACTGGAGATAAAAG 
      rev AGAAAGCTGGGTCTACAACTGGCCTGGAGATTG 
ORF 16 528 bp BCBL-1, gDNA for AAAAAGCAGGCTATGGACGAGGACGTTTTG 
      rev AGAAAGCTGGGTTTATCTCCTGCTCATCGC 
ORF 17 1662 bp BCBL-1, gDNA for AAAAAGCAGGCTATGAGCCTCCTAAGCCCC 
      rev AGAAAGCTGGGTCTACTGCTTGTTCAGGAG 
ORF 18 774 bp BC-1, gDNA for AAAAAGCAGGCTATGCTCGGAAAATACGTG 
      rev AGAAAGCTGGGTTTAAACCGCGTTGTTGTTAAAC 
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ORF 19 1650 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGCTGACATCAGAAAGG 
      rev AGAAAGCTGGGTTTAAACGACCGCGAGGAC 
ORF 20 963 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGTACGAGGTTTTTACAG 
      rev AGAAAGCTGGGTTCATGGACCTGAACAAGC 
ORF 21 1743 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGCAGAAGGCGGTTTTG 
      rev AGAAAGCTGGGTCTAGACCCTGCATGTCTC 
ORF 22 (FL) 2193 bp L74 *** for AAAAAGCAGGCTCCGCCGCTTTGTTTCTAATTCTC 
      rev AGAAAGCTGGGTCTAATAAAGGATGGAAAAC 
ORF 23 1215 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGTTACGAGTTCCGGAC 
      rev AGAAAGCTGGGTTTAGACGGTCAATAAAGC 
ORF 24 2259 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGCAGCGCTCGAGGGC 
      rev AGAAAGCTGGGTTTAGACCAGCGGACGGAC 
ORF 25 4131 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGAGGCGACCTTGGAG  
      rev AGAAAGCTGGGTCTAATACACCACCTTGTTTC 
ORF 26 918 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGCACTCGACAAGAGTATAG 
      rev AGAAAGCTGGGTTTAGCGTGGGGAATACCAAC 
ORF 27 873 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGCGTCATCTGATATTC 
      rev AGAAAGCTGGGTTTATTTAAAATTTAGAATC 
ORF 28 (FL) 309 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGAGCATGACTTCCCCG 
      rev AGAAAGCTGGGTCTAATCTGGCATGTATATTG 
ORF 28 d2 132 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATTCGCGTGTTCCTGGCGGC 
      rev AGAAAGCTGGGTCTAATCTGGCATGTATATTG 
ORF 28 ext 218 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGAGCATGACTTCCCCGTCTCC 
      rev AGAAAGCTGGGTTTAGGGAGGCTTGGTGGCCATTC 
ORF 29b 1056 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGCTTCAGAAAGACGCC 
      rev AGAAAGCTGGGTTTATTGTGGGGATATGGG 
ORF 30 234 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGGTGAGCCAGTGGATC 
      rev AGAAAGCTGGGTTCATTTCGCACCGGTGTC 
ORF 31 675 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGTCACAAAACAGAAAG 
      rev AGAAAGCTGGGTCTACGTATCTTTCGTTGATAG 
ORF 32 1365 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGATGCGCATGCTATC 
      rev AGAAAGCTGGGTCTAGCCATAGCGGCCTCG 
ORF 33 939 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGCTAGCCGGAGGCGC 
      rev AGAAAGCTGGGTTCAGACATTCGTAAGAGG 
ORF 29a 939 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGCTGCTCAGCCGTCAC 
      rev AGAAAGCTGGGTTTAAGGCCCTGGGCTTAC 
ORF 34 984 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGTTTGCTTTGAGCTCG 
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      rev AGAAAGCTGGGTTTAGAGTTGGTTGAGTCC 
ORF 35 453 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGACTCAACCAACTCTAAAAG 
      rev AGAAAGCTGGGTTTAGGGAGTTTCAGGGCAC 
ORF 36 1335 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGCGCTGGAAGAGAATG 
      rev AGAAAGCTGGGTTCAGAAAACAAGTCCGCG 
ORF 37 1461 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGAGGCCACCCCCACAC 
      rev AGAAAGCTGGGTCTACGGGCTGTGAGGGAC 
ORF 38 186 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGGATTTCTCCTATCTATC 
      rev AGAAAGCTGGGTTTAATAAATTGCTTCTTTATTTTTTTTC 
ORF 39 (FL) 1203 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCCGCGTTATAAGGAGCGACTG 
      rev AGAAAGCTGGGTTCTAAATGAATATCATTTG 
ORF 39d2 240 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCCGCGTTATAAGGAGCGACTG 
      rev AGAAAGCTGGGTTCTAAATGAATATCATTTGCGTTTC 
ORF 40 1374 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGCAACGAGCGAAGAAAC 
      rev AGAAAGCTGGGTCAAGCAGGGACAGTAGG 
ORF 41 618 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGCCGGGTTTACTCTG 
      rev AGAAAGCTGGGTTCAAAATAAAGATAAAAG 
ORF 42 837 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGTCCCTGGAAAGGGCC 
      rev AGAAAGCTGGGTTTATTTTGAAAAAAGGGAAAC 
ORF 43 1818 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGTTGAGGATGAACCCG 
      rev AGAAAGCTGGGTCTATGCACTTCCAGGACAAG 
ORF 44 2367 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGACAGCTCGGAAGGG 
      rev AGAAAGCTGGGTTCAGTAGATCAGAGTAGTC 
ORF 45 1224 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGCGATGTTTGTGAGG 
      rev AGAAAGCTGGGTTCAGTCCAGCCACGGCCAG 
ORF 46 767 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGACGCATGGTTGCAAC 
      rev AGAAAGCTGGGTTTACTGCTCCAACAGGCC 
ORF 47(FL) 504 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCCAGGCATCGGCAGCCTCTAC 
      rev AGAAAGCTGGGTTTATTTTCCCTTTTGACC 
ORF 47(CyD)   BC-1, gDNA for AAAAAGCAGGCTCCGCCCACTCTATCCACTTCGCC 
      rev AGAAAGCTGGGTTTATTTTCCCTTTTGACC 
ORF48 (FL) 1209 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCATGGAGGTGTGTATCCCA 
      rev AGAAAGCTGGGTTCAATCATACTCATCGTC 
ORF 48 cyt 586 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGAGGTGTGTATCCCAATTC 
      rev AGAAAGCTGGGTCCGCCGGAACTCCACATC 
ORF 48 ext 552 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATTACCTCGGACGTGAGAC 
      rev AGAAAGCTGGGTTCAATCATACTCATCGTCGG 
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ORF 49 909 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGACATCGAGAAGGCCC 
      rev AGAAAGCTGGGTTTATTGTATACTGAACAATG 
ORF 50 1896 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGAAAGAATGTTCCAAG 
      rev AGAAAGCTGGGTTCAGTCTCGGAAGTAATTAC 
K 8 720 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGCCCAGAATGAAGGAC 
      rev AGAAAGCTGGGTCTATACCTGCTGCAGCTG 
K8(spliced) 330 bp BC-1-RNA * for AAAAAGCAGGCTCCGCCATGCCCAGAATGAAGGAC 
      rev AGAAAGCTGGGTCTATACCTGCTGCAGCTG 
K 8.1  594 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCCAGGACCACGCGAATTCG 
      rev AGAAAGCTGGGTCTATTTCTGCCGTTTTCTG 
K8.1(B) 
(spliced) 722bp BC-1-RNA for AAAAAGCAGGCTCCGCCCAGGACCACGCGAATTCG 
      rev AGAAAGCTGGGTCTATTTCTGCCGTTTTCTG 
K8.1 (CyD) 98 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCCAGGACCACGCGAATTCG 
      rev AGAAAGCTGGGTCTATTTCTGCCGTTTTCTGC 
ORF 52 396 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGCCGCGCCCAGGGGC 
      rev AGAAAGCTGGGTTCAGTCATCAACCCCCGC 
ORF 53 333 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGACAGCGTCCACGGTG 
      rev AGAAAGCTGGGTCTATGCATGGACCACCTC 
ORF 54 957 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGAACAACCGCCGAGGC 
      rev AGAAAGCTGGGTCTAAAACCCAGACGACCC 
ORF 55 684 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCGTCTCCATGGTACCATGTC 
      rev AGAAAGCTGGGTCTATGTCGAACCTATCGC 
ORF 56 2532 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGAGACGACATACCGC 
      rev AGAAAGCTGGGTTTAACTGGCCAGTCCCAC 
ORF 57 (FL) 828 bp Z8 *** for AAAAAGCAGGCTCCGCCATGATAATTGACGGTGAG 
      rev AGAAAGCTGGGTTTAAGAAAGTGGATAAAAG 
ORF 57 
(spliced) 1368 bp BC-1-RNA for AAAAAGCAGGCTCCGCCATGGTACAAGCAATGATAG 
      rev AGAAAGCTGGGTTTAAGAAAGTGGATAAAAG 
K 9 1350 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGACCCAGGCCAAAGAC 
      rev AGAAAGCTGGGTTTATTGCATGGCATCCCATAAC 
K 10 2091 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGGGTCCTCTGGGACG 
      rev AGAAAGCTGGGTTCAATGTAGACTATCCCAAATG 
K 10.5 942 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGTACCACGTGGGACAG 
      rev AAAAAGCAGGCTTTAGTCATCACATGTAAC 
VIRF3 1607 bp Plasmid-DNA ****  for AAAAAGCAGGCTCCGCCATGGCGGGACGCAGGCTTACC 
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      rev AAAAAGCAGGCTTTAGTCATCACATGTAAC 
K 11 1404 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGCACAGTTTGTTTTTTG 
      rev AGAAAGCTGGGTTTAGTCTCTGTGGTAAAATG 
ORF 58 1074 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGTGCCGCCTGGACAGTG 
      rev AGAAAGCTGGGTTTAGCCAACAACTTTATTTATTAC 
ORF 59 1191 bp Z8 for AAAAAGCAGGCTCCGCCATGCCTGTGGATTTTCAC 
      rev AGAAAGCTGGGTTCAAATCAGGGGGTTAAATG 
ORF 60 918 bp Z8 for AAAAAGCAGGCTCCGCCATGGATTCAGTTGATCGA 
      rev AGAAAGCTGGGTTCACAAATCGTCAGTCAC 
ORF 61 2279 bp Z8 for AAAAAGCAGGCTCCGCCATGTCTGTCCGGACATTTTG 
      rev AGAAAGCTGGGTCTACTGACAGACCAGGCAC 
ORF 62 996 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGAAGGTGCAGGCTGAAAATG 
      rev AGAAAGCTGGGTTTACAGAAACACAGTCCAG 
ORF 63 I  1642 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCATGGACGGCACAGACGCTC 
      rev AGAAAGCTGGGTTACAAGTGACTCTTGGTAAACGC 
ORF 65 513 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGTCCAACTTTAAGGTG 
      rev AGAAAGCTGGGTCTATTTCTTTTTGCCAGAG 
ORF 66 1290 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGCCCTGGATCAGCGC 
      rev AGAAAGCTGGGTTCAGGAGGAACACTTCCC 
ORF 67 816 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGAGTGTCGTTGGTAAG 
      rev AGAAAGCTGGGTTCAGCTGGGCCTCATCCAAAC 
ORF 67.5 243 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGAGTACGCGTCTGACCAG 
      rev AGAAAGCTGGGTTCAGGGCCGTGCCCGCGC 
ORF 68 (FL) 1638 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCATGTCACGAGGCAGAAGC 
      rev AGAAAGCTGGGTTCAAGCGTACAAGTGTGACGTC 
ORF 68 d2 1120 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCGCAGACCTGTGCGAGATC 
      rev AGAAAGCTGGGTTCAAGCGTACAAGTGTGACGTC 
ORF 68 d1 463 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCATGTCACGAGGCAGAAGC 
      rev AGAAAGCTGGGTTTAGGCATAGTCCTCGAAGAAAC 
ORF 69 678 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGAGACCCCGATATGC 
      rev AGAAAGCTGGGTTTATAGGGCGTTGACAAG 
K 12cyt 107 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCAGTGGCCAGCGTGGCCCC 
      rev AGAAAGCTGGGTTCAGTGCGCGCCGTTGC 
K 13/ORF 71 567 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCATGGCCACTTACGAGGTTC 
      rev AGAAAGCTGGGTCTATGGTGTATGGCGATAG 
ORF 72 774 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGCAACTGCCAATAAC 
      rev AGAAAGCTGGGTTTAATAGCTGTCCAGAATG 
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K 14 1047 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGATACACACATTTTTTG 
      rev AGAAAGCTGGGTTCACTGGGTGGATAGGGG 
K 14.1 231 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGCCTAGAGGGCGCACC 
      rev AGAAAGCTGGGTCTAGGACCACAGCATTTTTC 
ORF 74 (FL) 1029 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCATGGCGGCCGAGGATTTCC 
      rev AGAAAGCTGGGTCTACGTGGTGGCGCCGGAC 
ORF 74 
(CyD) 125 bp BC-1, gDNA for AAAAAGCAGGCTCCGCCTCCCTCTTTAGGCAGAGG 
      rev AGAAAGCTGGGTCTACGTGGTGGCGCCGGAC 
ORF 75 (I)  2034 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCATGGCCTACGACGTCACTG 
      rev AGAAAGCTGGGTTAGTAGGCCTGCTCCCCCATGGCC 
K 15 303 bp BCBL-1, gDNA for AAAAAGCAGGCTCCGCCAAGGAAAAAAAAGTGGTGGC 
      rev AGAAAGCTGGGTCTAGTTCCTGGGAAATAAAACC 
K15 (spliced) 1470 bp P-Allel Plasmid-DNA ***** for AAAAAGCAGGCTCCGCCATGAAGACACTCATATTC 
      rev AGAAAGCTGGGTCTAGTTCCTGGGAAATAAAACC 
 
* kindly provided by Gergana Iotzova, Genzentrum, München, Germany 
** kindly provided by Maria Roupelieva, Genzentrum, München, Germany 
*** lambda (L) and cosmid clones (Z), Russo et al, PNAS 1996, 93:14862-7 
**** kindly provided by Prof. Dr. Paula M. Pitha-Rowe, Oncology Center, The Johns Hopkins 
University School of Medicine, Baltimore, Maryland 21231, USA. 
***** kindly provided by Prof. Dr. Thomas F. Schulz, Institut fur Virologie, Medizinische Hochschule 
Hannover, D-30625 Hannover, Germany.  
 
The oligonucleotides were obtained from Invitrogen (Karlsruhe, Germany) and 
thermo hybaid (Ulm, Germany). 
3.1.10  Molecular weight markers 
Gene Ruler 100 bp DNA ladder MBI Fermentas, St. Leon-Rot, 
Germany 
Gene Ruler DNA 1 kb ladder MBI Fermentas, St. Leon-Rot, 
Germany 
See Blue Plus 2 Prestained Protein Standard  Invitrogen, Karlsruhe, Germany 
low range 
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3.1.11  Kits 
Pharmacia GFX PCR DNA Gel Purification Amersham-Pharmacia, Freiburg, 
Germany 
Qiafilter Plasmid Maxi Kit    Qiagen, Hilden, Germany 
Qiagen Plasmid Mini Kit    Qiagen, Hilden, Germany 
3.1.12  Antibodies 
3.1.12.1 Primary antibodies 
3F10 Rat Mab against HA tag, Roche Diagnostics, 
Mannheim, Germany  
9E10 Mouse Mab against Myc tag, Santa Cruz 
Biotechnology, Heidelberg, Germany 
3.1.12.2 Secondary antibodies 
peroxidase-conjugated: 
Goat Anti-Rat    Dianova, Hamburg, Germany 
Goat Anti-Mouse   Dianova, Hamburg, Germany 
3.1.13  Enzymes 
T4 DNA Polymerase  New England Biolabs, Beverly, USA 
Calf Intestinal Alkaline   New England Biolabs, Beverly, USA 
Phosphatase (CIP)   New England Biolabs, Beverly, USA 
BP Clonase    Invitrogen, Karlsruhe, Germany 
LR Clonase    Invitrogen, Karlsruhe, Germany 
Topoisomerase I   MBI Fermentas, St. Leon-Rot, Germany 
T4 DNA Ligase    MBI Fermentas, St. Leon-Rot, Germany 
Vent DNA Polymeras  New England Biolabs, Beverly, USA 
Polynukleotid Kinase  New England Biolabs, Beverly, USA 
Proteinase K    Invitrogen, Karlsruhe, Germany 
Restriction Endonuclease  MBI Fermentas, St. Leon-Rot, Germany 
Roche Diagnostics, Mannheim, Germany 
New England Biolabs, Beverly, USA 
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3.2  Methods 
3.2.1  Bacterial cell culture 
3.2.1.1 Cultivation of bacteria 
E. coli bacteria were grown in LB medium or on LB agar plates. Incubation was 
performed at 37°C with constant shaking. 
 
LB Medium (1 l):    10 g Bacto Tryptone 
5 g Bacto Yeast Extract 
5 g NaCl 
 
LB Agar:     LB Medium with 1.5 % Agar 
Selection Medium:  LB Medium with 100 µg/ml Ampicillin and/or 50 
µg/ml Kanamycin 
3.2.1.2 Preparation of competent bacteria 
For preparation of competent bacteria a single clone of DH5α was picked and grown 
in 20 ml TYM medium at 37°C to an OD600nm of 0.8. The bacterial culture was diluted 
with 100 ml TYM and incubated at 37°C until an OD600nm between 0.5-0.9 was 
reached. Subsequently, the culture was again diluted by adding 500 ml of TYM and 
incubated at 37°C. At an OD600nm of 0.6 the culture was rapidly chilled down on ice 
water. The following incubations were performed at 4°C or on ice. The bacteria were 
distributed to two 50 ml tubes and centrifuged 5 min at 3500 rpm (Heraeus Varifuge 
3.0R). The supernatants were discarded and the pellets were resuspended in 100 ml 
ice-cold TfB I. After 40-50 min incubation on ice, the bacteria were centrifuged 10 min 
at 2500 rpm (Heraeus Varifuge 3.0R). The supernatants were discarded and the 
pellets were resuspended in 25 ml ice-cold TfB II. Aliquots of 0.4 ml were added to 
prechilled 0.5 ml reaction tubes and stored at -80°C. 
 
TYM:     10 mM MgS04 
 100 mM NaCl  
20 g/l Bacto Tryptone 
5 g/l Bacto Yeast Extract 
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TfB I:     30 mM KAc 
     50 mM MnCl2 
     100 mM KCl 
     10 mM CaCl2 
     15 % (v/v) Glycerol 
 
TfB II:     10 mM MOPS pH 7.0 
     75 mM CaCl2 
     10 mM CaCl2 
     15 % (v/v) Glycerol 
both buffers sterilized by filtration (Ø0.2 µm) and stored at 4°C. 
3.2.1.3 Transformation 
Different volumes of the ligation reaction mixture (5, 10, 20 µl) were added to 100 µl 
competent bacteria, mixed with 80 µl of 50 mM CaCl2 and incubated 30 min on ice. 
After the heat shock, 1 min 42°C, 800 µl LB medium were added and bacteria were 
cultivated for 1 h at 37°C. Then 100 µl were taken and plated on LB agar plates with 
antibiotic(s). The residual bacteria were centrifuged (4000 g, 5 min), resuspended 
and plated the same way. The plates were incubated o/n at 37°C. 
3.2.2  DNA techniques 
3.2.2.1 Purification of plasmid DNA 
Plasmid DNA was purified with the Pharmacia GFX Micro Plasmid Kit in small scale 
and the Qiafilter Plasmid Maxi Kit in large scale according to the manufacturer’s 
instructions. 
3.2.2.2 Determination of DNA concentration 
The concentration and purity of the purified DNA was determined by measuring the 
UV absorbance at 260 and 280 nm. The DNA concentration was calculated with the 
OD260nm  (1 OD260nm = 50 µg/ml dsDNA or 33 µg/ml ssDNA). The purity was 
estimated with the OD260nm/OD280nm ratio, with a ratio of ca. 1.8 indicating a low 
degree of protein contamination. 
3.2.2.3 Restriction endonuclease digestion 
Restriction endonuclease reactions were performed according to the manufacturer’s 
recommendations. In general, 1.5 µg DNA was digested for 2 h at the appropriate 
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temperature with 10-20 U enzyme. Efficacy of the cleavage reaction was controlled 
by agarose gel electrophoresis. 
3.2.2.4 5’-Dephosphorylation reaction 
5’-dephosphorylation reactions of plasmid vector DNA after restriction endonuclease 
cleavage were performed with the calf intestinal alkaline phosphatase (CIP). 50 U 
CIP were added to about 1.5 µg restriction enzyme digested plasmid DNA. After 30 
min incubation at 37 °C was stopped and the DNA was isolated by agarose gel 
electrophoresis. 
3.2.2.5 Nested polymerase chain reaction (PCR) for recombinatorial 
cloning 
Polymerase chain reactions (PCR) were performed with Vent DNA polymerase which 
consists of an integral 3’-5’ proofreading exonuclease activity. Vent is produced as a 
recombinant protein in E.coli. The Vent DNA polymerase gene was isolated from the 
archae Thermococcus litoralis. As PCR templates we used either genomic DNA 
isolated from BCBL-1 cells, KSHV phage or cosmid clones from BC-1 cells 
(Cesarman et al., 1995), KSHV BAC DNA generated from virus of BCP-3 cells, or 
cDNA prepared from BC-1 cells for the amplification of spliced genes. 
 
Table 3: Primer construction for nested polymerase chain reaction (PCR) 
 
1.  attB1 internal    for AAAAAGCAGGCTCCGCCATGXXXXXXXXXXXXXXX 
2.  attB1 internal    rev     AGAAAGCTGGGTCTAXXXXXXXXXXXXXXXXXXXX 
3.  attB2 external   for      GGGGACAAGTTTGTACAAAAAAGCAGGCT 
4.  attB2 external   rev    GGGGACCACTTTGTACAAGAAAGCTGGGT 
 
yellow box: attB1/attB2 sequence red letters: Kozak sequence 
bold letters: ATG (for) and stop (rev) codon XXXXX: homologous for and rev sequence 
(18 – 22 nucleotides, 3’ end G or C, app. 
60°C annealing  temperature)  
1st PCR: 
Components: 
10 x Thermo Pol Buffer     5 μl 
Internal Forward Prime  10 pmol/μl  1μl 
Internal Reversed Primer  10 pmol/μl  1 μl 
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Template (genomic DNA)     1 μg 
respectively, 200 ng Plasmid DNA 
dNTP Mix    10mM   0,7 μl 
Vent Polymerase   2 u/ml   0,7 μl 
H2O        add 50 μl 
The PCR reactions were performed as hot start reactions, i.e. first the PCR-device 
was started and after heating 0,7 μl of Vent Polymerase was added.  
 
 
1st step    2nd step      3rd step 
(hot start: add Vent polymerase) 
 
 
                                                     
 
 
 
     (ca. 10-15 cycles)      
 
Figure 9a: Diagram of the 1st PCR procedure 
2nd PCR: 
Components: 
10 x Thermo Pol Buffer     5 μl 
External Forward Primer  10 pmol/μl  1μl 
External Reversed Primer  10 pmol/μl  1 μl 
Template (1st PCR Reaction)    10 μl 
dNTP Mix    10mM   0,7 μl 
Vent Polymerase   2 u/ml   0,7 μl 
H2O        add 50 μl 
Heating             
94°C, 2,5 min 
Annealing              
55°C, 30 sec 
 
Synthesis              
68°C, 30 – 180 sec 
 
Denaturation           
94°C, 15 sec
Synthesis              
68°C, 7min 
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1st step      2nd step            3rd step        4th step 
(hot start: add Vent   
polymerase) 
 
  
 
                                                     
 
 
 
(5 cycles)                (ca. 10-15 cycles) 
Figure 9b: Diagram of the 2nd PCR procedure 
 
The time of synthesis was varied according to the length of the expected product (60 
sec per 1000 bp) 
3.2.2.6 Isolation of DNA fragments 
DNA fragments were separated by agarose gel electrophoresis, stained with 
ethidium bromide, and detected with UV light (366 nm). The gel slice containing the 
DNA fragments was cut out and the DNA was isolated using the Pharmacia GFX 
PCR DNA Gel Purification Kit according to the manufacturer’s instructions. 
3.2.2.7 Phenol/chloroform extraction and ethanol precipitation 
Proteins were removed from DNA preparations by extracting twice with 1x volume 
phenol/chloroform and once with 1x volume chloroform. After vigorous vortexing for 
10 s, the solution was centrifuged at 14000 rpm (microcentrifuge) for 1 min and the 
upper DNA containing phase was recovered. Then 0.1x volume 3 M NaAc pH 5.2 
and 2.5x volume 100% EtOH (cold) were added, and incubation at -80°C was 
performed for 20 min. The precipitated DNA was centrifuged down at 14000 rpm for 
30 min (4°C). Then the pellet was washed once with 70% EtOH (cold). After another 
centrifugation step (14000 rpm, 15 min, 4°C, microcentrifuge) the EtOH was carefully 
removed, the pellet was air-dried at RT and finally resuspended in H2O.  
Heating         
94°C, 2,5 min 
Annealing          
45°C, 30 sec 
 
Synthesis          
68°C, 30 – 180 sec 
 
Denaturation       
94°C, 15 sec
Synthesis        
68°C, 7min 
Annealing          
55°C, 30 sec 
 
Synthesis          
68°C, 30 – 180 sec 
 
Denaturation       
94°C, 15 sec
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3.2.2.8 Ligation 
For ligation, approximately 50 ng of vector DNA was used at a molar vector/insert 
ratio of about 1:3. The reaction was performed in a total volume of 20 µl 1x reaction 
buffer (MBI Fermentas) with 5 U T4 DNA Ligase (MBI Fermentas). First, vector and 
insert were mixed in reaction buffer, then the ligase was added. After incubation o/n 
in a waterbath at 16°C, the ligation was either directly transformed into competent 
bacteria or stored at -20°C until further usage. 
3.2.2.9 Recombinatorial cloning (RC) 
3.2.2.9.1 The BP reaction 
Components: 
PCR- product    2-7 μl 
pDONR 207     1 μl 
BP Reaction buffer (5x)   1.5 μl 
BP Clonase     1 μl 
 
The reaction was incubated at 25° C for at least 60 min. After incubation, 2 μl of 
proteinase K were added and incubated for 10 min at 37°C.  
1 μl of the reaction was transformed into 50 μl DH5α, DH10B or Top10 competent 
cells by electroporation. 500 μl S.O.C. medium was added and incubated at 37°C for 
1h. The transformation reaction was spread on LB plates containing 1,5 μg/ml 
gentamycin. The plates were incubated for 16 hours. 
From single colonies miniprep DNA was isolated. Minipreparations were treated with 
RNAse, precipitated with ethanol and stored in TE. The preparations were digested 
with the restriction endonucleases Pst I and Apa I to determine the correct size of the 
inserted fragment.  
3.2.2.9.2 The LR reaction 
Components: 
Purified Entry Clone (150ng/μl)  2 μl 
pGBKT7     1 μl 
pGADT7     1 μl 
LR Reaction Buffer (5x)   1.5 μl 
Topoisomerase    1μl 
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LR Clonase     1 μl 
Further steps were performed as described under ‘The BP reaction’. The 
transformation reaction was divided in two parts. One was spread on LB plates 
containing 50 μg/ml kanamycin for pGBKT7 (bait vector), the other on ampicillin 
plates (100μg/ml) for pGADT7 (prey vector). 
3.2.2.10 Agarose gel electrophoresis 
Analysis of DNA fragments and plasmids was performed by agarose gel 
electrophoresis in 1x TAE. In general agarose concentration was between 1 and 3 % 
in 1x TAE. The agarose was solubilised by heating in a microwave oven. Ethidium 
bromide was added to a final concentration of 0.25 µg/ml (2,5 µl stock to 100 ml) just 
before pouring the gel. Probes were mixed with 0.17x volume loading buffer. Gels 
(6.5 x 9.5 cm) were run horizontally at 80-120 V. DNA was detected with UV light, 
λ=254 nm or λ=366 nm to cut out specific fragments. 
 
Loading Buffer (6x in water)  MBI Fermentas, St. Leon-Rot, Germany 
20x TAE:     800 mM Tris 
400 mM NaAc 
40 mM EDTA 
adjusted to pH 7.8 with acetic acid 
Ethidium Bromide (stock):  10 mg/ml 
3.2.2.11 Plasmid construction 
3.2.2.11.1 Inserting the recombination cassette into bait and prey vectors  
A conversion cassette (Gateway) containing a chloramphenicol resistance (Cmr) and 
a lethal gene (ccdB) flanked by the λ att sites was inserted blunt end into the Sma I 
restriction site of the Y2H bait vector pGBKT7 (Kmr) and the Sma I of the prey vector 
pGADT7 (Apr) (Clontech) resulting in pDEST-GADT7 and pDEST-GBKT7 (pGADT7 
and pGBKT7 containing the attR-cassette are also referred to as destination vectors). 
Destination vectors must be constructed and propagated in DB3.1 cells, a gyrA462 
strain of E. coli because the ccdB gene is lethal to other strains.  
The reading frame cassettes are blunt-ended, i.e., they are inserted in both 
orientations and have to be tested for the proper orientation.  
The destination vectors were used to make fusion proteins of a KSHV protein and the 
Gal4-activation domain (prey constructs), respectively KSHV protein and DNA- 
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binding domain. Thus, it is essential to establish the correct reading frame, starting 
with the Sma I restriction side, where the cassette has been inserted, over the attR1 
site, the KSHV- gene, the attR2 side and activation or binding domain. In our case, 
we had to use reading frame cassette B.  
3.2.2.11.2 Cloning the PCR products into the donor vector 
114 PCR products with 25-bp terminal attB sites (+ 4Gs) were converted to entry 
clones by performing BP reactions, in which the PCR products containing attB sites 
recombine with a donor vector containing attP sites. The resulting entry clones are 
flanked by attL sites. As a donor vector we chose pDONR207 carrying a gentamycin 
resistance gene (Gmr). 
3.2.2.11.3 Subcloning of the array into bait and prey vector 
The LR reaction is used to create expression clones. The recombination proteins cut 
to the left and right of the gene within the attL sites in the entry clone and ligate it to 
the corresponding attR site in the destination vector, creating an expression clone. 
The resultant 25-bp attB sites (attB1 on the N-terminus and attB2 on the C-terminus) 
created by the LR reaction are derived from the attL sites (adjacent to the gene), 
whereas the distal sequences are derived from the attR sites. 
The KSHV array consisting of the 114 different entry clones was transferred by LR 
reaction into the Y2H plasmids pGADT7 (ampicillin resistance) and pGBKT7 
(kanamycin resistance). Due to the three different resistances involved it was possible 
to perform the subcloning from the donor vector into bait and prey vector in a one-
tube-reaction: The LR reactions were transformed into the competent E. coli and the 
bacteria were plated on kanamycin and ampicillin plates to obtain both bait and prey 
plasmids. 
3.2.3  Tissue culture 
3.2.3.1 Cultivation and cryoconservation 
The KSHV-infected PEL cell line BCBL-1 was cultured in RPMI 1640 supplemented 
with 20% fetal calf serum, 100 IU/ml penicillin, 100 µg/ml streptomycin and 2 mM L-
glutamine. Cells were induced for 48 h with 3 mM n-butyrate. 293 and Hela cells 
were cultured in DMEM/10% FCS plus supplements at 37°C and 5% CO2. For 
cryoconservation cells were detached with trypsin and centrifuged at 300 g for 5 min 
at 4°C. Then the cells were resuspended in 1 ml FCS/10% DMSO (4°C) with a final  
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concentration of 0.5-1x107 cells/ml and transferred to cryovials which were cooled to 
-80°C in a “Cryo 1°C Freezing Container” (Nalgene). Subsequently, the vials were 
transferred to liquid nitrogen for long term storage. Frozen aliquots were quickly 
thawed at 37°C in a waterbath, 10ml DMEM was added and after centrifugation at 
300 g for 5 min, the supernatant was removed. Subsequently, cells were 
resuspended in complete medium and transferred to cell culture dishes. 
3.2.3.2 Calcium phosphate transfection 
For transient transfection, cells were grown on 10 cm Ø dishes to 60-70% 
confluency. 500 µl of 2x HBS pH 7.05 was added to a 15 ml Falcon tube. In another 
tube, 20 µg DNA was combined with 500 µl 250 mM CaCl2. The tube with the 2x 
HBS was vortexed while the DNA/CaCl2 solution was added dropwise. The solution 
was incubated at RT for 15-20 min to allow the formation of the Calcium-DNA to 
precipitate. Subsequently, the suspension was mixed with 6 ml fresh medium and 
was added to the cells after removal of the old medium. The next day, protein 
expression was assessed by immunofluorescence. 
 
2x HBS pH 7.05:    50 mM HEPES 
1.5 mM Na2HPO4x 2 H2O 
280 mM NaCl 
12 mM glucose 
3.2.4  Protein techniques 
3.2.4.1 Co-immunoprecipitation 
Co-immunoprecipitation was performed using the plasmids pGBKT7 and pGADT7 
with T7 promoter and recombinant vaccinia virus vT7 expressing the T7 RNA 
polymerase (NIH AIDS repository). 293 cells were cultured on 10 cm dishes and 
infected with vTF-7 at a MOI of 10 in serum-free medium. One hour after infection, 
cells were transfected with 10 µg of each of the two expression plasmids by calcium 
phosphate transfection. Expression was controlled using a GFP plasmid under the 
control of a T7 promoter. After 24 h, cells were lysed by incubation in 1 ml of NP-40 
lysis-buffer (1% NP-40, 140 mM NaCl, 5 mM MgCl2, 20 mM Tris pH 7,6, 1 mM PMSF) 
for 30 min on ice. Lysates were centrifuged for 10 min at 20,500 g and 4°C to remove 
unsolubilized material and precleared with 50 µl of preequilibrated protein G-
Sepharose.  
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Supernatant was divided into two parts. Subsequently, proteins were precipitated 
from the supernatant by adding 1 μg of the anti-HA (Roche) antibodies or the anti-
myc (Santa Cruz) antibodies, respectively and 50 µl of protein G-sepharose beads, 
each overnight at 4°C. Beads were washed three times with ice-cold NP-40 buffer 
and were resuspended in 2xSDS protein sample buffer. Cellular subfractions and 
total cell lysates were additionally sonified for 30 s. Samples were boiled for 10 min 
and directly analyzed by SDS-PAGE or stored at -20°C. 
Equilibration of protein G-Sepharose: 1.5 g protein G-Sepharose was washed 3x and 
resuspended with NP-40 lysis-buffer to obtain a 50% slurry. 
3.2.4.2 SDS-PAGE 
Gel electrophoresis was performed with minigels using the Protean II system (Bio-
Rad) with 12 to 20% gels (80 x 50 x 1 mm). The solution for generating the 
separation gel was mixed and, after pouring, the gel was overlaid with isopropanol. 
After polymerization, the isopropanol was sucked of the gel. The stacking gel solution 
was poured on top of the separation gel and a comb was fixed. After polymerization, 
the glass plates containing the gel were assembled in the gel electrophoresis 
apparatus. Samples or pellets from immunoprecipitation were resuspended in the 
appropriate amount of 2xSDS protein sample buffer and heated for 5 min to 95°C. 
After cooling to RT, the samples were centrifuged for 2 min at 14000 rpm 
(microcentrifuge) and loaded on the gel together with a protein standard. Separation 
was performed at 150 V constant current for 1-2 h. 
 
Separation Gel :      12%___ 15%  20%__ 
Acrylamide / Bisacrylamide (37.5:1)   2 ml  2.5 ml  3.33 ml 
1.5 M Tris pH 8.8      1.25 ml 1.25 ml 1.25 ml  
10 % SDS       50 µl  50 µl  50 µl 
H2O        1.675 ml 1.175 ml 0.343 ml 
10 % APS       20 µl  25 µl  25 µl 
TEMED       2.5 µl  2.5 µl  2.5 µl 
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Stacking gel:       5%____ 
Acrylamide/ Bisacrylamide (37.5:1)    1.35 ml 
0.5 M Tris pH 6.8       0.625 ml 
10 % SDS        25 µl 
H2O         1.53 ml 
10 % APS        12.5 µl 
TEMED        2.5 µl 
Electrophoresis buffer (10 x):    50 mM Tris 
384 mM glycine 
0.1% SDS 
3.2.4.3 Western blot 
Proteins were blotted to nitrocellulose membranes (Schleicher & Schuell) using the 
Trans-Blot SD Semidry Transfer Cell (Bio-Rad). A piece of nitrocellulose membrane 
and two pieces of filter paper and two sponges of the same size as the gel were 
soaked with transfer buffer. A sponge, a piece of filter paper, the nitrocellulose 
membrane, the gel, another piece of filter paper and again a sponge were packed. 
Then, air bubbles were removed by rolling a test tube over the sponge, and 
subsequently the package was clamped into the transfer tank with the nitrocellulose 
facing the anode. Blotting was performed with 100 V for 1 h. Proteins were detected 
after 2 min incubation in Ponceau staining solution.  
The membranes were labeled with a pen and washed several times with H2O to 
remove the Ponceau staining solution. Unspecific binding sites were blocked by 
incubation in TBST (TBS, 0.05% Tween 20), 5% skim milk powder, 0.02% NaN3 
either 1 h at RT or o/n at 4°C. Then incubation with the first antibody was performed 
in 5-10 ml TBST (used also in the following washing and incubation steps) at 4°C o/n. 
After five washing steps of 15 min with ca. 200 ml buffer each, incubation with the 
secondary antibody, coupled to peroxidase, was performed in 15 ml buffer at RT for 
1 h followed by washing 5x 10 min in 200 ml buffer. The blotted proteins were 
detected using the ECL Western blotting detection system (Amersham-Pharmacia) 
according to the manufacturer’s instructions. The membrane was exposed to 
BIOMAX-MR autoradiography films (Eastman-Kodak) for different time periods and 
films were developed using an automatic film developing machine. 
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Transfer buffer (1 l):     Ponceau solution (100 ml):  
Tris base   5.8 g     Ponceau S    0.5 g 
Glycine   2.9 g     Glacial acetic acid   1 ml 
SDS    0.37 g    H2O     98.5 ml 
Methanol   200 ml 
H2O    to 1l 
 
Antibody dilution 
 
rat anti-HA tag      1 : 1000 
Roche Diagnostics, Mannheim, Germany 
mouse anti-myc tag      1 : 1000 
Santa Cruz Biotechnology, Heidelberg, Germany 
goat anti-mouse peroxidase coupled    1 : 5000 
Jackson, Hamburg, Germany 
goat anti-rat peroxidase coupled    1 : 5000 
Jackson, Hamburg, Germany  
3.2.5  Yeast cell culture 
3.2.5.1 Competent yeast cells 
To produce competent yeast cells, first a preculture had to be prepared: 10 ml YEPD-
medium was inoculated by a colony of the yeast strain Y 187, respectively AH109. 
The preculture was shaken overnight at 30°C. 
The next day, the preculture was added to 250 ml of fresh YEPD-medium and 
let grow at 30°C until it reached a density of 0,6 at OD600.  The cells were harvested in 
ten 50 ml Falcon tubes at 2000 Upm (930 x g, 5 min, 4°C). The supernatant was 
removed and the cells were resuspended in 12,5 ml SBEG-solution (each) and 
subsequently pelleted another time. The resulting cell pellet was resuspended in 500 
μl SBEG-solution. The 500 μl cellsuspension was splitted into 100 μl aliquots, filled 
into microlitertubes and put into liquid nitrogen. The aliquots were stored at - 80°C. 
YEPD medium:      to 800 ml H2O add: 
  
for liquid medium:      10 g yeast extract 
 20 g peptone 
 20 g dextrose 
 add H2O to 1 liter, autoclave 
 
for solid medium: add 14 g agar before 
autoclaving  
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SBEG solution:      91,1 g Sorbitol 
      5 ml Bicine 1M pH 8,35 
      15 ml Ethylenglycol (3%) 
 add 500 ml H2O 
3.2.5.2 Transformation into yeast 
For a transformation, a microlitertube with 100 μl competent yeast cells (Y187 or 
AH109) was thawed quickly in a waterbath at 37°C. Subsequently, 1 μg of the 
plasmid pGBKT7, respectively pGADT7, was pipetted into the thawed yeast cells of 
the appropriate yeast strain and mixed carefully by the pipet. Afterwards, 750 μl 
PEG/Bicine-solution was added and again mixed by the pipet. First of all, this reaction 
was incubated at 30°C for 1 h, then at 45°C for 5 min. The next step was to pellet the 
cells for 2 min at 3500 Upm (ca. 2700 x g, table centrifuge). The supernatant was 
removed by a pasteurpipet and the pellet was resuspended in 1ml NB-buffer by a 
pipet. Again, cells were pelleted, as described above, but only 800 μl of the 
supernatant was removed. The pellet was resuspended in the remaining 200 μl 
supernatant and plated on an appropriate yeast plate.  
 
Bicine:      stock solution pH 8,35, sterile 
 
 
PEG/Bicine solution:    PEG 1000 (40%) 
   Bicine, pH 8,35, sterile 
 
NB buffer:       3 ml NaCl 5M 
(0,15M NaCl/10mM Bicine)   1 ml Bicine 1M pH 8,35, sterile 
 
Transformed yeast cells were grown to an OD600 of 0,6 in YEPD medium. Yeast cells 
were stored in 15% glycerol at -80 °C. 
3.2.5.3 Mating and selection by a robot device 
The steps involving a robotic workstation (Biomek 2000; Beckman Coulter) were 
performed in the lab of Peter Uetz in the ‘Institut für Toxikologie und Genetik’ in 
Karlsruhe.  
The prey array, consisting of 111 haploid yeast transformants, was divided onto two 
plates, lacking leucine (the transformed yeast vector pGADT7 provides a leucine 
auxotrophy). By applying 5μl of appropriate yeast glycerol stock, 96 colonies were 
placed on the first plate and 15 on the second one (single-well microtiter plates). For 
reasons of transportabability the yeast-transformed bait array was treated the same  
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way, apart from being placed on plates lacking tryptophan. The second prey plate 
was splitted into triplets of 3 x 32 individual colonies. The 17 ‘free places’ per third 
were filled up with preys from the first plate. This procedure was done by hand in our 
lab. 
By robot device, each element on the prey plate was quadruplicated, thus we 
obtained 384 elements per plate. The quadruplication assures reproducibility of 
screening results.  
Bait colonies from -Trp plates were picked and grown overnight in 20 ml YEPD at 
30°C. The bait-medium was transferred into empty microtiter plates. The pins of the 
384-pin replicator were dipped into the BD fusion-expressing culture and placed 
directly onto a fresh single-well microtiter plate containing solid YEPD medium. This 
procedure was repeated for each of the 112 baits.  
Between transfer steps, the tool must be sterilized by sequential immersion into a 
20% bleach solution (20sec), sterile water (1 sec), 95% ethanol (20 sec), and sterile 
water (1 sec). The level of these liquids should be 2 to 4 mm from the base of the pin 
and care must be taken that the ethanol does not evaporate.  
In the next step, the prey array, transformed into haploid Mat a yeast strain, was 
picked up with sterilized pins and transferred directly onto the Mat α colonies 
expressing a single protein as a BD fusion, so that each of the 384 BD yeast spots 
per plate received different AD yeast cells. The plates were incubated for 1 or 2 days 
at 30°C to allow mating. 
For selection the colonies were transferred to single-well microtiter plates containing 
solid -Leu -Tryp dropout medium using the sterilized pinning tool. The colonies were 
grown for 2 days at 30°C until they were 1mm in diameter. This was an essential 
control step because only diploid cells that contain Leu and Trp markers on pGADT7 
and pGBKT7, respectively, will grow on this medium. This step also helps recovery of 
the colonies and increases the efficiency of the next selection step.  
For the next step the colonies were transferred to a single-well microtiter plate 
containing solid -His -Leu -Trp (+ 3AT) dropout medium using the sterilized pinning 
tool and grow at 30°C for up to 10 days (or longer if there is little or no background 
growth) to select two-hybrid positive diploids. 
The stringency of the screen can be varied by adding different amounts of 3AT, an 
inhibitor of the His3 gene product. In many cases (10% to 20%), the haploid strain 
expressing the BD fusion has transcriptional self-activation properties. These haploid  
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strains can be titrated on plates lacking histidine and containing increasing amounts 
of 3AT (3mM, 10mM, 20mM, 
50mM). The highest level of 3AT tolerated should be added to the -His -Leu -Trp 
plates for selection of two-hybrid positive diploids. In many cases, the transcriptional 
activity is very strong (>200 mM 3AT), so that not all self-activators can be 
eliminated.  
The interactions were scored by looking for growing colonies that were significantly 
above the background (by size) and that were present in at least 3 out of the 4 
colonies. In rare cases 2 out of 4 growing colonies were scored positive, when these 
2 colonies were extraordinary large.  
 
Dropout medium:      to 800 ml H2O add: 
For liquid medium: 1,7 g yeast nitrogen base 
without amino acids 
5 g ammonium sulfate 
20 g dextrose 
1,4 g dropout powder 
add H2O to 1 liter, autoclave 
 
For +3AT dropout medium:    add 3 mM 3-aminotriazole 
 
For solid medium:  add 16 g agar before 
autoclaving 
cool to 45°C and pour into 
appropriate plates.  
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4  RESULTS 
4.1.  Generation of KSHV arrays in Y2H bait and prey vectors 
4.1.1  Amplification of KSHV genes 
To identify previously unknown viral protein-protein interactions in the human γ 
herpesvirus KSHV by performing a Y2H matrix screen, we amplified each viral ORF 
by PCR (Figure 10, Figure 11). For transmembrane proteins, extra- and intracellular 
domains were cloned separately. In total, we cloned 93 full-length proteins and 20 
protein domains. Five genes for which splicing events are known were additionally 
generated from cDNA of KSHV positive cell lines or cDNA clones provided by other 
scientists (see Table 2), in order to amplify the spliced version. These five viral genes 
are: (i) one of the three alternatively spliced transcripts encoded by the K8 locus of 
KSHV (Gruffat et al., 1999; Lin et al., 1999; Seaman et al., 1999; Sun et al., 1998; 
Zhu et al., 1999), (ii) K8.1B (one of two alternatively spliced proteins identified by 
Chandran et al.(Chandran et al., 1998) in the genomic K8.1 region), (iii) the spliced 
gene product of ORF57 (Bello et al., 1999; Kirshner et al. 2000; Lukac et al., 1998; 
Lukac et al., 1999), (iv) the spliced K10.5/10.6 transcript encoding vIRF-3 (also 
termed LANA-2) (Rivas et al., 2001; Lubyova and Pitha, 2000) and (v) one of the 
eight exons of the K 15 gene (Choi et al., 2000b; Glenn et al., 1999; Poole et al., 
1999). K 15 exists in two variants, M and P. It is thought that the P variant (for 
'prototype') represents the original KSHV sequence and that the M variant (for 
'minor') is the result of a recombination event with a currently unknown related 
rhadinovirus (Choi et al., 2000b; Glenn et al., 1999; Poole et al., 1999). The P variant 
was used as a template for the K15 (spliced) PCR product. 
 
Figure 10: PCR products.  
7 out of 113 PCR products. The generation of ORF 37 failed here, yet succeeded later on. 
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Figure 11: The KSHV-
genome: 
The KSHV genome 
consists of approximatly 
100 genes, among them 
numerous glycoproteins, 
three versions of which 
were generated: a full 
length PCR-product, a 
cytoplasmatic and an 
external domain.  
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4.1.2  Adding attB sites to both ends of the PCR-product 
First, each gene was individually amplified by PCR using forward and reverse 
primers with a similar annealing temperature of approximately 60°C. The internal 
forward primer contained a 12 nucleotide partial attB1 site, a translational initiation 
consensus sequence (KOZAK), the initiation codon ATG, and 15 to 22 homologous 
nucleotides. The internal reverse primer contained a 12 nucleotide partial attB2 site, 
a stop codon and 15 to 22 homologous nucleotides. By reamplification with common 
29 nucleotide forward and reverse primers the complete attB1 and attB2 sites were 
added to both ends (Figure 12).  
 
 
Figure 12: PCR-product with attB1 and attB2 sites.  
Indicated in black are the partial attB-sides of the internal individual primer. Indicated in blue are the 
external primers, which complete the attB-sites in the second PCR round. 
4.1.3  Cloning the PCR-products into the entry vector 
Each PCR-product was cloned into the entry vector pDONR207 by recombinatorial 
cloning (RC). The collection of KSHV-genes in this vector represents the KSHV 
ORFeome. 
Starting with these vectors, the whole array or single genes can easily be subcloned 
into different destination vectors. Thus, an entire genome or subset of genes of 
interest can be examined in various ways in a short amount of time. 
4.1.4  Subcloning into the bait and prey vector 
Subsequently, the array was subcloned into the Y2H bait and prey vectors pGBKT7 
and pGADT7, which contain kanamycin and ampicillin resistance genes. As all three 
vectors contain different resistance genes, the subcloning could be performed in a 
one-step reaction (Figure 13). The two arrays thus consist of each viral ORF fused to 
either the DNA binding or activation domain. 
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Figure 13: Recombinatorial cloning. 
113 PCR-products were cloned into the donor vector by BP reaction. Subsequently, these sequences 
were subcloned in one step into two different vectors. The transformed E.colis were spread on 
kanamycin and ampicillin plates. 
4.1.5  Transformation into yeast and arrangement of the plates 
The bait array in vector pGBKT7 was transformed into the haploid Y187 yeast strain 
of the Mat a mating type, the prey array in the vector pGADT7 into the AH 109 yeast 
strain of the Mat α mating type. Transformed yeast cells were grown to an OD600 of 
0,6 in YEPD medium and stored in 15% glycerol at -80 °C. 
The 111 haploid prey transformants were distributed onto two plates, lacking leucine 
(the transformed yeast vector pGADT7 provides a leucine auxotrophy). 96 colonies 
were placed on the first plate and 15 colonies on the second one (single-well 
microtiter plates) by applying 5μl out of the yeast glycerol stock. The yeast-
transformed bait array was placed on plates lacking tryptophan. 
The second prey plate was divided into triplets of 3 x 32 individual colonies. The 17 
‘free places’ per triplet were filled with preys from the first plate. 
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Plate I: 96 haploid prey transformants on a single-well microtiter plate 
 
 
Plate II: 3x32 prey transformants, 17 transformants of first plate reoccur on the 
second one 
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4.1.6  The robot-assisted steps 
 
 
Figure 14: Mating and selection of diploids and two-hybrid positives, using an automated 
pinning device  
Step 1: Haploid yeast cells expressing the binding domain-ORF fusion protein (bait) were transferred 
from a liquid culture to solid medium. Step 2: Haploid cells from the activation domain array (prey-
array) were transferred with the same tool onto the BD-ORF fusion-expressing cells for mating. Step 3: 
After 2 days of growth, the colonies were transferred to -Leu-Trp medium to allow growth of diploids. 
Step 4: After another 2 days of growth, the diploid cells were transferred to two-hybrid selective plates 
(-Trp-Leu-His), on which visible colonies started to grow after a few days. (Weak two-hybrid positives 
may, however, take up to 3 weeks or more to form colonies.) (according to Cagney et al., 2000) 
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The next steps were robot-assisted: Individual yeast transformants of both arrays 
were mated with each transformant of the opposite mating type. Diploid yeast 
transformants were transfered onto plates selecting for the presense of both bait and 
prey vectors, and subsequently onto plates selecting for activation of the Gal4-
controlled HIS auxotrophy (Figure 14). 
4.2  Identification of KSHV protein-protein interactions 
4.2.1  Analysis of Y2H data 
The Y2H matrix screen of 113 viral KSHV genes and more than 12,000 viral protein 
interactions resulted in the identification of 125 interacting protein pairs, 
corresponding to approximately 1% of the total number of pairs. Y2H screens 
generate significant numbers of false positive interactions which are not reproducible. 
This occurrence of histidine auxotroph colonies can result from mutations of the host 
strain. In order to enable rapid detection of reproducible two-hybrid interactions, we 
tested every pairwise combination in quadruplicates. Interactions in the Y2H screen 
were scored positive if three or four out of four matings were positive (Figures 15a-c) 
or if two out of four were positive and the colonies were large compared to average 
colonies (Figure 15d). 
 
Figure 15a: Protein-protein interactions of bait ORF 60  
Four out of four colonies: 
6 C: K5d2 
10F: ORF 52 
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3 G: K10 
5 G: K11 
8 G: ORF 61 
1 H: ORF 67.5 (weak) 
2 H: ORF 68d2 (weak) 
Three out of four: 
3 D: ORF 23 
7 G: ORF 60 
ORF 60 serves as an example for a highly connected viral protein. The interactions visible here are 
not the only ones ORF 60 is involved in, as ORF 60 also shows interactions as bait with the prey plate 
II and as prey protein with other baits. 
 
 
Figure 15b: Protein-protein interactions of bait ORF 61 
8 G: ORF 61 
Single strong interaction (four out of four). In contrast to bait ORF 60 hardly any background is visible. 
 
 
Figure 15c: Protein-protein interactions of baits DR2/1; ORF73 (c-terminal); vIRF3 
Interacting preys DR2/1: 
three out of four: 
1 F: DR2/1 
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2 F: K 10 
false positive:  
2 B: two out of four 
3 H: one out of four 
ORF 73 (c-terminal): no colonies growing 
K10.5+K10.6:  
false positive: 
11A: one out of four 
11F: one out of four 
11G: one out of four 
12H: one out of four 
 
One of the disadvantages limiting the number of detectable interactions is the high 
percentage of selfactivating baits (Figure 15e). These sequences encode 
polypeptides that, when fused to a binding domain, can activate transcription on their 
own. 15 proteins were found to be strong activators when fused to the Gal4 DNA-
binding domain, and thus could only be analyzed under more stringent conditions in 
the bait vector, using the competitive inhibitor 3AT. But even under more stringent 
conditions, nine baits remained self-activating. However, self-activating ORFs in the 
bait vector can still be tested unidirectionally in the prey vector as fusions with the 
Gal4 activation domain and are thus not completely lost for the screen.  
 
Figure 15d: Protein-protein interactions of bait ORF 23  
Two out of four growing colonies were counted as positive interaction if they grew large and against 
faint background.  
Interacting preys:  
four out of four: 
1 H: ORF 67.5 
three out of four: 
9 D: ORF 28/d1 
11D: ORF 30 
both better visible after a longer time of incubation. 
two out of four: 
3 F: ORF 45 
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2 G: K 9 
false positive: 
10A: one out of four 
 
 
Figure 15e: Protein –protein interactions of ORF 30: 
Selfactivating bait: 
An inherent problem of Y2H screens is the high number of selfactivating baits (10-20%). This number 
can be reduced by increasing the stringency of the screen adding higher amounts of 3AT. In our case, 
the transcriptional activity of nine baits (from initially 15 selfactivating baits) was so strong that they 
could not be eliminated. Among the self-activating baits was ORF 30. 
4.2.2  Protein-protein interactions identified by Y2H matrix screen 
In total, 12.432 protein-protein interactions between different KSHV ORFs were 
tested and 125 were found to be positive. Three genes were introduced into the 
screen in only one of the two Y2H vectors: 
1) ORF28 d2 and ORF63 II could only be cloned into the prey vector 
(pGADT7). 
2) ORF73, which contains numerous internal repeats, could not be amplified 
by PCR, neither by using genomic-DNA, nor a cDNA clone. Instead, the C-terminal 
part of ORF73 was used as a bait. Unfortunately, it turned out to be self-activating. 
Almost all interactions could only be observed in one direction, i.e. the interaction 
could only be detected if one interaction partner was fused to the activation domain 
and the other to the binding domain, but not vice versa. 
In figure 16 the baits are indicated on the vertical axis and the preys on the horizontal 
axis. The mirror axis is indicated by red boxes, selfactivating baits by yellow boxes. 
The 125 positive protein interactions are indicated by black boxes. 
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The histogram on top of the table indicates the number of interaction partners of each 
viral ORF. Along the viral genome, proteins with many interaction partners cluster in 
two regions: between ORF23 and ORF31 and between ORF52 and ORF67.5. 
Figure 16: Protein-protein interactions in KSHV identified by yeast two-hybrid matrix 
screen 
Each of the individual bait clones was tested against each of the individual prey clones. Bait clones 
are scheduled on the vertical axis, prey clones on the horizontal axis. Self-activating baits are 
indicated in yellow. 125 positive protein interactions are indicated by black boxes, the mirror axis by 
red boxes.  
Distribution of protein interactors along the KSHV genome: There are two clusters of viral hubs 
between ORF23 and ORF31 and between ORF52 and ORF67.5 within the KSHV genome. 
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4.3  Characterization of interactions 
4.3.1  Classification of protein interactions in KSHV 
Based on the known or suggested function of the participating proteins the 
interactions were divided into five functional cat 
egories: DNA-replication, gene regulation, virion structure / morphogenesis, virus-
host interactions and unknown function. Viral proteins were divided into 4 classes 
depending on wether they are specific for KSHV or possess orthologs in HSV- 1 (α), 
CMV (β) or EBV (λ).  
To reduce the number of false positive interactions, we scrutinized all 125 
interactions detected by co-immunoprecipitation.  
4.3.2  Co-immunoprecipitation of Y2H positive interactions 
The Y2H bait and prey vectors used in this study express the insert either as c-Myc- 
or HA-tagged protein under the control of a T7 promotor. This feature allowed to test 
each protein- protein interaction by co-immunoprecipitation (CoIP) without the need 
of subcloning the viral genes into new vectors. Bait and prey vectors of interacting 
partners were transfected into 293 cells. Simultaneously, cells were infected with 
recombinant vacciniavirus expressing T7 polymerase. Cell lysates were split into two 
parts and precipitated with either anti-c-Myc or anti-HA antibodies. Each precipitate 
was separated on two polyacrylamide gels. On the left side of each gel precipitating 
and on the right side co-precipitating proteins are indicated. The precipitations were 
performed to control for expression levels and correct size. Out of the 125 viral 
protein-protein interactions found with the Y2H-system, 62 could were also detected 
by co-immunoprecipitation (approximately 50 percent) (Figure 17). This number of 
false positive interactions was also reported in the literature (Mrowka et al., 2001). 
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Figure 17: Co-immunoprecipitations 
Protein interactions were verified by CoIP. Cloned KSHV ORFs were expressed from pDEST-GBKT7 
and pDEST-GADT7 bait and prey vectors as myc- or HA-tagged proteins by transfection into 293 cells 
and simultaneous infection with recombinant vaccinia virus vTF-7 expressing T7 RNA polymerase. 
Cell lysates were split and precipitated with either anti-myc or anti-HA antibodies. Each precipitate was 
separated on two polyacrylamide gels. On the left side of each gel precipitating and on the right side 
co-precipitating proteins are indicated. Coprecipitating proteins are indicated by asterisks (*). 
4.3.3.  Expression, function and homologues genes of interacting KSHV 
proteins 
For each interacting KSHV protein, the function or certain characteristics as portrayed 
in the literature and homologous genes in other herpesviruses were listed in the 
Figure below (Figure 18). By adding these informations, the plausibility of protein 
interactions can be assessed comparing functional information of interacting partners 
(as far as a function it is known). Listing homologous genes in other herpesvirus 
genera may hint at conserved protein interactions. It may thus provide the opportunity 
to predict interactions in other herpesvirus genomes. 
The proteins were divided into five functional groups (red: DNA replication and 
nucleotide metabolism, yellow: gene regulation and signalling, green: virion structure 
and morphogenesis, blue: proteins involved in virus-host interaction, grey: unknown 
function). More than 70 % of all protein interactions occurred between viral proteins 
belonging to different functional classes. In general, interacting proteins are not more  
Results 
 
  66
likely to belong to the same functional class than random pairs of proteins (only 1.1-
fold enrichment over random pairs of proteins, p=0.334), suggesting that the majority 
of viral proteins either have multiple, previously unknown functions, or are assigned 
incorrectly. Significantly increased numbers of intra-class interactions were only 
identified between proteins belonging to the gene regulation and unknown functional 
classes. Whereas interactions between proteins involved in host interaction were 
most highly suppressed (as expected, interactions between proteins involved in both 
host interaction and replication were significantly increased. Interactions between 
proteins with unknown function are significantly overrepresented, implying that they 
are within the same functional group (other than host interaction) and part of identical 
complexes or processes. Subsequently, we partitioned viral ORFs into 8 phylogenetic 
classes based on wether they are conserved across HSV-1 (α), CMV (β), and EBV 
(γ). The KSHV-specific phylogenetic class is dominated by proteins involved in host 
interaction, and the αβγ phylogenetic class (containing proteins present in all three 
subfamilies) by structural proteins and those involved in replication. 
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Figure 18: Protein-protein interactions in KSHV. 
Indicated for each bait and prey clone are the function or putative function of the ORF and 
homologous genes in HSV-1 (α), CMV (β) and EBV (λ).  
Viral proteins were divided into five functional groups marked by different colours: red: DNA 
replication, nucleotide metabolism, yellow: gene regulation and signalling, green: virion structure, 
morphogenesis, blue: proteins involved in virus-host interaction, grey: unknown function. 
Positive protein-protein interactions identified by Y2H matrix screen were scrutinized by co-immuno- 
precipitation.  
4.3.4  Viral protein-protein interaction map in KSHV 
The interaction map was created on the basis of the data out of the Y2H matrix 
screen (Figure 19). Self-interacting, viral proteins are depicted with a blue square. 
Different domains and full length constructs of the same protein are defined as one 
dot. Similar to Figure 18, proteins are divided into five functional groups which are 
marked by different colours. This visualizes that proteins of the same functional group 
tent to cluster in certain regions.  
We see that some proteins are forming hubs, which means that they have many 
interaction partners, e.g. ORF29b and ORF67.5 (packaging proteins), ORF60 
(ribonucleotide reductase), K10 and K11 (viral interferon regulatory factors).  
Another feature of this interaction map is that it makes interaction partners of 
unknown proteins visible. Unknown proteins interacting several times with proteins 
belonging to one functional group might as well be a member of this group. For 
example: ORF53 is interacting with K5 and K3, these proteins are homologous to  
Results 
 
  70
each other and they are both involved in the ubiquitinylation and subsequent 
downregulation of MHC I (Coscoy and Ganem, 2000; Coscoy and Ganem, 2001a). 
Thus, specific conclusions concerning the function of ORF53 might be drawn from 
these interactions. 
 
Figure 19: KSHV protein-protein interaction map. 
Protein interaction map in KSHV evaluated by Y2H screen. KSHV proteins are indicated as nodes, 
protein interactions as either hatched (found only by Y2H) or solid (confirmed by CoIP) edges. The 
same colours as in Figure 17 were chosen to distinguish between functional groups: red: DNA 
replication, nucleotide metabolism, yellow: gene regulation, green: virion structure, morphogenesis, 
blue: proteins involved in virus-host interaction, grey: unknown function. Squares were added to self-
interacting proteins. 
4.4  Conserved protein interactions between herpesvirus 
subfamilies 
KSHV encodes ORFs with 31, 38 and 54 orthologs in the main representatives of the 
three α, β and γ herpesvirus subfamilies, HSV-1, CMV and EBV. The 54 KSHV ORFs 
with orthologs in EBV possess an average sequence identity of 35.1%. Among these 
54 proteins 30 are involved in viral protein interactions as shown in our data set, but  
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their average similarity is not increased (34.5%) when compared to the 24 non-
interacting proteins (36.0%). However, hubs (proteins that interact with >5 other 
proteins) are more conserved, i.e. there is a positive correlation between homology 
and the number of interaction partners. Within the group of conserved proteins, there 
is a significant correlation between protein interactions and homology which is 
statistically significant for EBV (p=0.046). The core set of 22 KSHV ORFs that have 
orthologs in all three other herpesviruses have an average homology of 40.9%. Within 
this core set the 10 viral proteins which were found to interact have an average 
homology of 43.1%. This indicates that this most basic set of proteins is functionally 
important and thus more conserved. Since interactions between highly homologous 
proteins are conserved, we predict 56 interactions in EBV (Figure 20), 22 in CMV 
(Figure 21) and 19 in HSV-1 (Figure 22).  
 
Figure 20: Predicted protein interaction in EBV. 
54 KSHV ORFs have orthologs in EBV, among which 30 have protein interactions. To self-interacting 
proteins a square was added. The colours of the nodes indicate the function of the KSHV orthologs.  
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Figure 21: Predicted protein interactions in CMV 
38 KSHV ORFs have orthologs in EBV, among which 22 have protein interactions. It is striking, that 
only a few interactions according virus-host-interactions and gene regulation could be predicted. 
 
 
 
 
Figure 22: Predicted protein interactions in HSV-1 
31 KSHV ORFs have orthologs in EBV, among which 19 are predicted to interact. As in EBV and 
CMV, most conserved interactions belong to the group of virus replication and 
morphogenesis/structure. From the virus-host interaction group only UL13, the ortholog of KSHV 
ORF36 is predicted to interact in HSV-1. 
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5  DISCUSSION 
5.1  Analysis of protein-protein interactions 
5.1.1  Herpesviruses 
Surprisingly little is known about interactions between herpesviral proteins, 
particularly of herpesviruses which replicate poorly in cell culture including the human 
γ-herpesvirus KSHV. We know that more than half of the viral genes do not encode 
structural or replicatory proteins, but rather non-essential proteins mandatory for 
infection of the natural host. A considerable number of viral proteins share sequence 
and structural similarities with cellular proteins, however possess different functions. 
5.1.2  Choice of KSHV genes, domains and templates 
The first report on the KSHV sequence predicted 82 open reading frames (ORFs) 
(Russo et al., 1996). Several other genes including K4.1, K4.2, K8.1, K 
10.5, ORF67.5, K14.1, K10.7 (vIRF3) were added in later studies (Neipel et al., 1997; 
Jenner et al., 2001). Although cDNAs of five spliced genes were included in this 
study, this is probably not the complete set of spliced KSHV genes. Since for some of 
the KSHV genes it is controversially discussed whether they are spliced, we only 
included one exon (for example: K10/K10.1 (vIRF4) and K11/K11.1 (vIRF2)). For K8 
(3 exons), K15 (8 exons) and K8.1 (2 exons) only one exon was used in this study 
since the cDNA was not available. 
Moreover, there might be more spliced genes which are currently unknown and 
which are therefore not introduced in the Y2H screen. Therefore, it is advisable to 
use cDNA as PCR template, whenever possible. 
The open reading frames at the very left and the very right end of the KSHV genome, 
K1 and K15, are known to be highly variable (Lagunoff and Ganem, 1997; Lee et al., 
1998; Neipel et al., 1997b; Nicholas et al., 1998; Russo et al., 1996). Thus, different 
sequences can be expected, according to the PCR template which has been used. 
Proteins containing transmembrane regions will give false negative results since both 
bait and prey proteins have to be transported into the nucleus in order to 
transactivate the promotor of the selection gene in the Y2H system. To avoid this, all 
full-length open reading frames were screened for putative transmembrane domains  
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by the algorithms HMMTOP 2.0 (Tusnàdy et al., 2001) 
(http://www.enzim.hu/hmmtop/html/document.html) and TMpred (Hofmann and 
Stoffel, 1993) (http://www.ch.embnet.org/software/TMPRED_form.html). The two 
programs were used in parallel since both can produce false negative and false 
positive results, i.e. known domains are not found, and vice versa. In addition to 
these problems, the designated orientation of the transmembrane proteins given by 
these programs is not always correct.  
To reduce false negative results caused by transmembrane proteins, we also cloned 
separate domains of proteins with known or predicted transmembrane domains. 
Intriguingly, several predicted external domains interacted with intracellular proteins 
in the Y2H screen. In some cases, these interactions could even be validated by 
CoIP. In these cases, the transmembrane domains might have been falsely 
predicted, as the algorithms used only have an accuracy of 60-80%.  
Despite all efforts the array displays some blanks: ORF64, a gene of 8 kb was not 
included, and for ORF6 and ORF75 (3,4 and 3.9 kb, respectively) only the 5’ half 
could be cloned into bait and prey vector. To decrease the number of PCR-induced 
mutations, a polymerase with a proof-reading activity (Vent polymerase) was used. 
However, the possibility that some constructs of the array contain mutations cannot 
be excluded. All ORFs with positive interactions were sequenced from both sides, 
and only two mutations were found (both not shifting the reading frame), indicating 
that the number of mutated clones is probably low. 
5.1.3  ORFeome matrices versus cDNA libraires 
Genome-wide analyses can be performed in several ways. In general, either cDNA 
libraries or ORFeome matrices containing full-length cDNAs can be used. 
cDNA libraries are limited in several respects: First, they do not represent 
accurately the mRNA distribution of the cell, and rare mRNA’s may be 
underrepresented or lost in the library. Second, 66.6% of the clones in cDNA 
libraries, which express N-terminal fusion proteins, are in the wrong reading frame. 
In this study, the KSHV ORFeome was cloned by recombinatorial cloning 
(GATEWAY system). This cloning technology replaces restriction endonucleases and 
ligase by site-specific recombination and is highly efficient. The viral ORFs were 
amplified by PCR from initiation to termination codon using specific primers with 
attB1, respectively attB2 recombination sites at the 5’ end. The resulting PCR  
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products were recombined uni-directionally into a ‘donor’ vector to create ‘entry’ 
clones. This reaction is reversible and ORFs in the entry vector can subsequently be 
transferred efficiently by recombination into any ‘destination’ vector of interest.  
We converted the yeast vectors pGBKT7 and pGADT7 into destination vectors 
by cloning a conversion cassette into the multiple cloning site. 
These vectors were chosen because of their numerous useful features: Both vectors 
contain a T7 promoter and tag sequences at the 5’ end of the insert, so that protein-
protein interactions can be tested by co-immunoprecipitation without time-consuming 
subcloning into different vectors and without specific antibodies. 
Both contain strong yeast promoters which causes a high sensitivity in 
detecting protein-protein interactions. On the other hand, these vectors might have 
the disadvantage of a higher rate of false positive interactions. 
5.1.4  Features and disadvantages of the Y2H system  
During the past few years, the Y2H system has become an important technique for 
detecting protein-protein interactions in large-scale projects.  
The Y2H system produces a significant number of false positive and false 
negative results.  
The largest group of false positives is caused by so-called self-activating baits. 
These proteins encode polypeptides that, when fused to a binding domain, can 
activate transcription in the absence of any interacting partner protein. They can 
easily be identified by including a negative control into the screen, e.g. the empty 
vector pGADT7.  
False positives can be caused by mutations in the reporter gene or in the vector. 
They can be identified by repeating the screen at least once (here quadruplicates 
were made of each pairwise combination). In previous studies, the authors tried to 
reduce false positive interactions by statistical means or estimated true-positive 
interactions by extrapolating the results of a biochemical analysis of a small subset of 
interactions. Here, we tested all positive Y2H interactions in parallel by CoIPs. 
False negatives can be caused by different characteristics of the Y2H system. First, 
one or both proteins may fail to enter into the yeast nucleus (e.g. transmembrane 
proteins). Second, a protein may be unable to function as a fusion protein due to 
steric hindrance. Third, the interaction between the two proteins may depend on 
post-transcriptional modifications that are absent in the yeast cell.  
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A comparison of the two independent large-scale screens in Sacharomyces 
cerevisiae may provide some insight into how much false data is produced by this 
approach (Ito et al., 2000; Uetz et al., 2000). Ito and colleagues constructed a DNA-
binding domain hybrid and an activation domain hybrid for each of the ≈ 6000 
predicted yeast proteins. This approach resulted in 4,549 two-hybrid positives. Uetz 
and colleagues used another strategy: individual DNA-binding domain fusion proteins 
were tested against an array of ≈6000 separate activation domain transformants, and 
individual DNA-binding domain transformants tested against a library of all activation 
domain hybrids. This study resulted in the identification of 957 putative interactions. 
There is only a small overlap in the results among all three approaches, and neither 
the first nor the second study recapitulate more than ≈13% of the published 
interactions detected up to now by using conventional single protein analysis 
(Hazbun and Fields, 2001). Not only does this rather small fraction of overlapping 
interactions hint at a high number of false negatives, it also suggests that genome 
‘interactomes’ are larger than estimated by earlier studies. 
5.1.5  Validation of Y2H interactions by co-immunoprecipitation 
Most studies that have attempted to validate large-scale two-hybrid data have 
postulated that these data sets contain up to 50% false positives (Deane et al., 2002; 
Mrowka et al., 2001). When we verified our two-hybrid data by co-
immunoprecipitation, we found a similar percentage. To circumvent the need for 
producing specific antibodies for co-immunoprecipitation, bait and prey proteins were 
fused to an epitope-tag. An antibody directed against the tag – instead of the protein 
itself – was used for complex retrieval. But even for co-immunoprecipitation, there are 
some limitations: First, antibodies may exhibit cross-reactivity with proteins other than 
the immunogen. In this case several proteins not related to the interacting protein 
might be precipitated, which essentially leads to the generation of false positives. In 
overexpression systems, the CoIP might be false positive due to unspecific binding. 
The artificially introduced tag may interfere with protein folding, protein function, or 
the ability to interact with other proteins. 
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5.2  Local analysis of the KSHV interaction map 
Recently, the interactome of vaccinia virus, which is a member of the other family of 
large DNA viruses, poxviruses, was reported (McCraith et al., 2000). In this study, 
only 37 viral protein interactions were detected among 266 ORFs tested (~0,14 
interactions / ORF). In this study, we identified 125 viral protein interactions among 
the 88 ORFs in KSHV (~1.4 interactions / ORF), i.e. an approximately 10-fold higher 
frequency (Uetz et al., 2004). Several of these protein interactions have been shown 
before for KSHV or homologous proteins of other herpesviruses, thus confirming the 
effectiveness of our approach. The majority, however, has not been reported before. 
We identified 15 viral hubs with >5 protein interactions, including ORF29b (16 protein 
interactions), K10 (16), ORF60 (14), ORF67.5 (12), ORF28 (10), ORF23 (9), K11 (8), 
K5 (7), ORF31 (7), ORF57 (7), ORF9 (6), ORF41 (6) and ORF61 (6) (Figure 23a-c). 
The 15 viral hubs represent all functional classes and include three proteins ORF23, 
ORF28 and ORF31 with unknown function. Since viral hubs tend to be conserved 
between herpesviral subfamilies, they are potential targets for drug design. 
 
Figure 23a: Local viral subnet involving the ribonucleotide reductase subunits ORF60 and 
ORF61. 
The ORF60 and ORF61 ribonucleotide reductase subunit proteins were found to homodimerize. They 
also interact with numerous other proteins, especially with proteins involved in host interaction. 
Interactions between proteins of the same functional group were indicated by solid, between proteins 
of different functional groups by hatched bars. 
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Figure 23b: Local viral subnet involving the immediate early proteins ORF45, ORF50, ORF57 
and K8.1. 
These four proteins belong to the class of gene regulation and signalling and they are immediate early 
proteins. In addition ORF57 was found to homodimerize. 
 
 
Figure 23c: Local viral subnet involving the packaging proteins ORF29b and ORF67.5. 
ORF29b and ORF67.5 are DNA packaging proteins. ORF29b and ORF67.5 act as major hubs with 15 
and 12 viral interaction partners, respectively. 
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5.3  Biological implications of particular protein-protein 
interactions 
The interacting proteins were grouped into five functional categories: DNA-
replication, nucleotide metabolism, gene regulation, virion structure / morphogenesis, 
virus-host interactions, and unknown function. Out of the 125 KSHV Y2H 
interactions, a small subset of interactions shall be described in more detail. This 
subset was chosen on the basis of the following criteria: 1) the viral interaction has 
formerly been described in small-scale experiments, and 2) both interaction partners 
are known and the interaction appears to be both plausible and interesting. 
Table 4: Previously reported protein interactions in KSHV (including KSHV 
orthologs in other herpesviruses). 
Interaction 
 
Virus Protein Reference 
Orf9 – Orf41 HSV-1 polymerase and 
helicase subunit 
H. S. Marsden et al., J.Virol. 71, 
6390-6397 (1997). 
Orf25 – Orf65 KSHV  major and small 
capsid proteins 
P. Lo, X. Yu, I. Atanasov, B. 
Chandran, Z. H. Zhou, J.Virol. 
77, 4291-4297 (2003) 
Orf29b – 
Orf67.5 
HSV-1 Packaging 
proteins (HSV-1 
UL15 homolog) 
and Orf67.5 (HSV-
1 UL33 homolog) 
P. M. Beard, N. S. Taus, J. D. 
Baines, J.Virol. 76, 4785-4791 
(2002). 
Orf36 – Orf45 
 
KSHV Kinase A. von Geelen et al. personal 
communication 
Orf45 - K8 KSHV  immediate early 
proteins 
K. Ueda et al. personal 
communication 
Orf57 – Orf57 KSHV 
HSV-1 
Immediate early 
protein 
HSV-1: ICP27 
P. Malik and J.B. Clements, 
Nucleic Acids Research 32, 
5553–5569 (2004) 
Y. Zhi et al. Virology. 257341-
51(1999):.  
Orf50 (RTA) – 
Orf57 
KSHV The immediate 
early 
transcriptional 
activators 
P. Malik et al. J.Gen.Virol. 
85:2155-2166 (2004) 
Orf50 (RTA) – 
K8 
KSHV The immediate 
early 
transcriptional 
activators 
Y. Izumiya et al., J.Virol. 77, 
1441-1451 (2003). 
Orf60 – Orf61 KSHV Ribonucleotide 
reductase 
subunits 
Y. Sun and J. Conner, 
Biochem.J. 347 Pt 1, 97-104 
(2000). 
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Orf60 – Orf60 HSV-1 homodimerization 
of ribonucleotide 
reductase subunit 
(HSV-1 UL40) 
J. Conner et al., Biochemistry 
32, 13673-13680 (1993). 
Orf61 - Orf61 HSV-1 homodimerization 
of ribonucleotide 
reductase subunit 
(HSV-1 UL39) 
J. Conner et al., Biochemistry 
32, 13673-13680 (1993). 
K12 – K12  KSHV homodimerization 
of kaposin  
S. Kliche et al., Mol.Cell 7, 833-
843 (2001). 
 
5.3.1  Structural viral proteins and proteins involved in morphogenesis 
KSHV particles comprise an icosaedric capsid surrounded by a protein matrix termed 
tegument and a plasma membrane containing a variety of glycoproteins termed 
envelope. The capsid consists of the mayor (ORF25) and minor (ORF26) capsid 
proteins constituting hexon and penton structures. The small basic capsid protein 
(ORF65) is located at the tip of the hexon structures and was suggested to connect 
capsid with tegument. In this study, we detected that ORF65 interacts with ORF25 as 
shown before, but also with the tegument protein ORF63. On the other hand, ORF63 
interacts with the protein ORF67.5, which is involved in packaging viral DNA into 
capsids. The two packaging and terminase proteins ORF29b and ORF67.5 act as 
major hubs with 15 and 12 viral interaction partners, respectively (Figure 23c). They 
constitute the most complex interaction subnet in this study and are connected to 
DNA packaging (ORF68), capsid (ORF25, ORF65), tegument (ORF34, ORF75) and 
even envelope proteins (K8.1), as well as to proteins involved in capsid egress 
(ORF69). Their homologs in HSV-1, UL15 and UL33, form a heteromultimeric 
complex with UL28. However, they also interact with proteins involved in viral 
replication, including the ORF9 polymerase, ORF41 helicase and ORF59 processivity 
factor. Moreover, ORF9 and ORF59 interact with the third packaging protein, ORF68, 
suggesting that the three ORF29b-ORF67.5-ORF68 packaging proteins link viral 
replication to virion assembly. Another interesting outcome within this functional class 
is the high connectivity of several proteins with unknown function including ORF23, 
ORF28 and ORF30 with the packaging proteins ORF29b and ORF67.5 suggesting a 
similar or related role for these proteins (Figure 23c). 
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5.3.2  Ribonucleotide reductase subunits ORF60 and ORF61 
ORF60, which interacts with 13 other viral proteins, is one of the major hubs of this 
analysis. The small and large subunits of the viral ribonucleotide reductase, ORF60 
and ORF61, interact with each other, similar to their cellular and vaccinia virus 
homologs (Kashlan et al., 2002, McCraith et al., 2000). The ribonucleotide reductase 
catalyses the conversion of all four ribonucleoside diphosphates to the corresponding 
desoxyribonucleoside diphosphates and thus plays an essential role in the de novo 
synthesis of DNA in all living organisms. Both ORF60 and ORF61 also self-interact. 
Such homodimerization was also reported for the HSV-1 homologues UL39 and 
UL40 (Conner et al., 1993). These characteristics suggest a heterotetrameric 
structure similar to eukaryotic class Ia ribonucleotide reductases and the 
ribonucleotide reductases of HSV-1 and EHV-4 (Kashlan et al., 2002; Sun and 
Conner, 2000). Not all herpesviral ribonucleotide reductases possess enzymatic 
reductase activity, and thus probably have adapted distinct biological functions during 
the evolution (Sun and Conner., 1999). HSV-1 UL40 (R1) for example has kinase 
activity in the C-terminal domain (missing in KSHV) and was suggested to act as a 
chaperone (Aurelian, 1998; Chabaud et al., 2003; Chung et al., 1989). A chaperone 
function might explain the multiplicity of interactions found for KSHV ORF60.  
HSV-2 R1 was reported to have anti-apoptotic properties able to protect cells 
against death triggered by TNF-receptor family (Langelier et al., 2002). 
In CMV, the ribonucleotide reductase homolog UL45 is an anti-apoptotic 
protein and mandatory for viral growth in endothelial cells (Brune et al., 2001).  
HSV-1 ribonucleotide reductase is a target for antiviral chemotherapy. 
Synthetic peptides inhibit the viral protein by preventing subunit association at the 
critical carboxy terminus of the small subunit (R2) (Liuzzi et al., 1994). 
 
Figure 24: Putative heterotetrameric structure of RR-complex. 
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5.3.3  The dUTPase ORF54 
The dUTPAse ORF54 is conserved in all three herpesvirus subfamilies and is also 
encoded by poxviruses and certain retroviruses. (Elder et al., 1992; McGeoch, 1990; 
Preston and Fisher, 1984). dUTPase is an enzyme involved in maintaining a low 
dUTP / dTTP ratio to minimize the lethal misincorporation of uracil into DNA by 
hydrolysing dUTP to dUMP and pyrophosphate (Shlomai and Kornberg, 1978). dUMP 
is a substrate for thymidylate synthase for the de novo dTTP synthesis. Herpesviral 
dUTPase-knock-out mutants have been reported to have an attenuated 
neurovirulence, a lacking ability to reactivate virus replication from latency (Pyles et 
al., 1992) and to possess an increased frequency of mutant formation (Pyles and 
Thompson, 1994). Most dUTPase active enzymes are homo-trimeric complexes (e.g. 
the human or the E. coli enzyme), The monomeric dUTPases are exclusively found in 
herpesviruses (McGeoch et al., 1995). There are several reports, suggesting that 
herpesviral dUTPase could be a target for specific chemotherapeutic agents, since 
there are additionally differences in the substrate specifity and the kinetics of 
dUTPase of viruses and their host cells (Kremmer et al., 1997; Williams, 1988, 
Studebaker et al., 2001; Studebaker et al., 2004). In this study, a bidirectional 
interaction between ORF54 and the kinase ORF36 was detected. A phosphorylation 
of the dUTPase was reported for the cellular dUTPase, vaccinia virus dUTPase and 
the dUTPase of EBV (Lirette et al., 1990; Sommer et al., 1996; Strahler et al., 1993). 
Since both proteins, ORF54 and ORF36 are conserved in all three herpesvirus 
subfamilies and the CMV ORF36 homolog UL97 is known to be responsible for 
ganciclovir resistance, this interaction might be a possible target for the development 
of inhibitors (Mendez et al., 1999). 
5.3.4.  Cluster of four immediate early proteins ORF45, ORF50, ORF 57 
and K8. 
We detected an interaction between the four immediate early proteins ORF50, 
ORF57, K8 and ORF45, as well as a dimerization of ORF57 (Figure 23b). 
Immediate early (IE) genes are the first class of the viral genes expressed 
after primary infection or reactivation. This class of genes is defined by their 
transcription following primary infection or reactivation. IE genes encode regulatory  
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proteins that modulate the expression of viral and cellular genes early after 
infection. They also play a crucial role in the switch from latency to the lytic life cycle. 
ORF 50 is known to be the most important protein during reactivation and functions 
as a strong transcriptional activator of the early and late genes of KSHV (Lukac et al., 
1999). ORF 50 was shown to act as a transcriptional activator of the ORF 57 and K8 
promotors and is mandatory for lytic replication of KSHV, similar to its EBV homolog 
RTA (AuCoin et al., 2004). It binds to the transcription factor RBP-Jκ and contains a 
transcriptional activation sequence at the C-terminus (Liang et al., 2002). 
ORF 57 is a spliced gene that is conserved throughout the herpesvirus family. It has 
a Herpes Simplex Virus type 1 homologue termed ICP27, which is an essential 
regulatory protein and acts at both transcriptional and post-transcriptional levels. 
Similar to ICP27, ORF 57 was shown to be a strong effector that can act on 
several levels to augment viral gene expression (Kirshner et al., 2000). Both, ICP27 
and ORF 57 protein were reported to shuttle between nucleus and cytoplasm (Bello 
et al., 1999; Mears et al., 1998). 
The results of this screen report a homodimerization of ORF 57, which was also 
shown for the HSV-1 protein ICP27 (Zhi, et al., 1999). The self-interaction of the 
KSHV ORF 57 was later on also shown by Malik and Clements (2004), who 
succeeded to report the interaction by GST-pull-down assay. 
The two ORF 50 and ORF 57 proteins are connected in several ways to each other. 
Both act post-transcriptionally and transcriptionally to regulate viral lytic gene 
expression and synergistically activate certain early and late KSHV promoters. ORF 
50 was reported to transactivate its own promotor and those of K8 and ORF 57 
(Byun et al., 2002). 
Here we detected the direct interaction between the two proteins ORF 50 and ORF 
57. This interaction was recently reported by Malik and colleagues (Malik et al., 
2004). A physical association between ORF50 and ORF57 was shown by pull-down 
assays, leading to the upregulation of the ORF50 promotor with augmentation of 
ORF50 activity by ORF57 protein, and vice versa. 
The immediate-early gene ORF45 is known as a phoshorylated tegument protein 
which can be found in virus particles, localizes in the cytoplasm and inhibits IRF-7, a 
cellular transcription factor inducing type I interferons (Zhu et al., 2002; Zhu and 
Yuan, 2003; Zhu et al., 2005). 
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ORF50, ORF57, K8 and ORF45 could either form a static heteromultimeric complex, 
or sequentially interact with each other. Their different localization supports the latter. 
Since the expression of ORF57 and K8 is transcriptionally regulated by ORF50, the 
ORF50-ORF57-K8 complex might be involved in a feedback loop. 
In our screen, ORF45 also interacts with ORF36, an autophosphorylated serine 
protein kinase located in the nucleus. This is remarkable, since ORF 45 is known to 
be a tegument protein, located in the cytoplasm. ORF 45 was reported to be 
phosphorylated by Park et al (Park et al., 2000). Our data suggest that ORF36 
regulates ORF45 by phosphorylation. On the basis of our results this interaction was 
confirmed by von Geelen and colleagues from the University of California, Davis, 
who found that ORF 36 binds ORF 45 and phoshorylated ORF 45 on a threonine 
residue (von Geelen, personal communication). 
The viral protein kinase, encoded by ORF 36 in KSHV, is conserved among all 
herpesviruses. Because of its low homology to cellular kinases and the fact, that the 
homologues of ORF36 in α-, β- and γ-herpesviruses have been reported to be 
essential for optimal virus growth (Besser et al., 2003; Gershburg and Pagano, 2002; 
Prichard et al., 1999), this viral protein kinase represents an excellent target for novel 
antiviral drugs. 
KSHV ORF36 was reported to activate JNK via MKK4 and MKK7 by 
phosphorylation. Activated JNK in turn regulates transcription by phosphorylating c-
Jun, ATF-2, and other transcription factors (Hamza et al., 2004). 
5.3.5  Ubiquitin ligases K5 and K3 
The antigen presentation pathway of major histocompatibility (MHC) class I plays an 
important role in alerting the immune system to virally infected cells. MHC class I 
molecules are expressed on the cell surface of all nucleated cells and present peptide 
fragments derived from intracellular proteins. These peptides are normally derived 
from original cell proteins but in a virally infected cell, peptides derived from viral 
proteins may also be presented. Virus-specific cytotoxic T lymphocytes (CTL) monitor 
cell surface MHC class I molecules for peptides derived from viral proteins and 
eliminate infected cells. 
Gammaherpesviruses and poxviruses share a family of immune evasion proteins. 
This family has been termed in several ways: modulators of immune recognition 
(MIR), Scrapins, or the K3 family (Coscoy et al., 2001b; Fruh et al., 2002; Guerin et  
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al., 2002). The hallmarks of the viral MIR-family are an amino-terminal RING-CH 
domain followed by two transmembrane domains. Since poxviruses and 
herpesviruses are unrelated viral families, it seems plausible that the viral RING-CH 
proteins originated from eukaryotic hosts (McFadden and Murphy, 2000). The 
existence of mammalian genes homologous to the MIR-family was confirmed by the 
reports of several investigators and is termed MARCH family (membrane-associated 
RING-CH family) (Bartee et al., 2004; Holzerlandt et al., 2002; Jenner and Boshoff, 
2002). The Kaposi's Sarcoma associated Herpesvirus encodes two proteins 
belonging to the MIR-family that share 40% sequence identity: K3 and K5. Expression 
of one of these proteins causes the rapid internalisation of MHC class I molecules 
from the plasma membrane by clathrin-dependent endocytosis (Ishido et al., 2000b). 
The MHC class I molecules are sorted into an acidic endocytic compartment where 
they are degraded by acidic proteases (Coscoy and Ganem, 2000; Lorenzo et al., 
2002). Furthermore, K5 can down-regulate the costimulatory molecules intracellular 
adhesion molecule-1 (ICAM-1) and B7.2 (Coscoy and Ganem, 2001a; Ishido et al., 
2000a). Indeed, a cellular homolog (cMIR) of K3 and K5 has been discovered, which 
appears to regulate the cell surface expression of B7.2 (Goto et al., 2003). This 
implies that K3 and K5 have evolved from a gene 'hijacked' by KSHV from the host 
genome. 
Both, K3 and K5 contain two transmembrane domains with cytosolically orientated N- 
and C-termini (Sanchez et al., 2002). In this study, both cytoplasmatic domains as 
well as full-length K3 and K5 genes were screened. 
A RING finger domain can also be found in some E3 ubiquitin ligases (Capili et al., 
2001; Joazeiro et al., 2000). Indeed, K3 and K5 function as E3 ubiquitin ligases. The 
expression of either protein results in ubiquitinylation of MHC class I molecules 
(Coscoy et al., 2001b; Hewitt et al., 2002). The addition of ubiquitin to specific lysines 
in the cytosolic domains of membrane proteins causes their internalization from the 
plasma membrane and functions as a signal to sort proteins for degradation (Hicke, 
1999; Pickart, 2001). 
In our screen we found several interactions involving K3 and K5. For example, we 
observed an interaction between the N- and C-terminal domain of K3, indicating 
either an intramolecular interaction or a multimerization of several K3 molecules. 
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Figure 25: K3 and K5 are E3 ubiquitin ligases.  
The N-terminal PHD domain of K3/K5 (with its associated E2 activity) is directed to the cytosolic tail of 
the target (MHC-I, B7.2, ICAM-I), where ubiquitinylation (Ub) takes place. The ubiquitinated 
cytoplasmatic region of the targets are recognized by the endocytic machinery, which promotes their 
removal from the cell surface and their subsequent degradation by the lysosome. In our yeast two-
hybrid screen we observed the interaction of the two cytoplasmatic domains of K3(according to 
Sanchez et al., 2002). 
 
Interestingly, K3 and K5 both interact with K7, a mitochondrial regulator of apoptosis. 
K7 connects active caspase-3 to Bcl-2 and thereby inhibits its apototic activity (Wang 
et al., 2002). Moreover, K7 targets a regulator of the ubiquitin- and proteasome-
mediated degradation machinery, PLIC1, to IκB and p53 (Feng et al., 2004). Since K3 
and K5 bind to a variety of different viral proteins, our data suggest that K3 or K5 form 
a complex with K7 which targets and possibly degrades other viral proteins. 
5.4  Further investigations concerning the topology of KSHV 
protein interaction network 
While cellular protein interaction networks exist for several model organisms, there 
had been no viral counterpart to date. In many complex networks (including protein 
interaction networks), most nodes have few, while some have many interaction 
partners (so-called hubs). It has been found that their degree distributions follow a 
power-law decay, and such networks are termed scale-free (Barabasi and Albert, 
1999). 
KSHV, like its cellular counterparts has relatively many hubs, a key characteristic of 
scale-free networks. However, in contrast to known cellular protein interaction 
networks, in which nodes with a single interaction partner are most abundant, the 
KSHV network has relatively few such “peripheral” nodes lying on the “edge” of the  
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network. Similar studies in VZV, mCMV and EBV indicated that the same 
characteristics hold true for other viruses as well (Baiker, Fossum, Kraus et al., 
personal communication). 
In KSHV, the degree distribution peaks at nodes with three neighbours. This unusual 
characteristic at low node degrees is one of the reasons that the viral networks 
appear as a single, highly coupled modules and presumably reflects their 
incompleteness as stand-alone networks. Further bioinformatical analyses revealed 
that the degree distribution of viral protein networks can be approximated by a power 
law. In contrast to previously identified cellular networks which possess bigger power 
coefficients, the power coefficient of the KSHV network was rather low (r=0.95). 
 
The Figures 26-32 were generated by Yu-An Dong, using the results of this study. 
 
 
Figure 26: Power-law degree distribution of two herpesviral (KSHV and VZV) networks in 
comparison to two high-confidence yeast networks.  
The dataset Yeast1 is derived from Schwikowski et al., Yeast2 from the DIP database (October 2004 
release). For the analysis of KSHV and VZV, the complete set of interactions detected by Y2H was 
used. For each network, node degrees k and their relative frequency (i.e. probability) are plotted on a 
bilogarithmic scale and fitted by linear regression. 
 
Another important characteristic of complex networks is the so-called small-world 
property (Watts and Strongatz, 1998). In a small-world network the average distance 
between any two nodes is short (short characteristic path length or the six degrees of 
separation phenomenon) and local neighborhoods are more densely connected (high 
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clustering coefficient). Both viruses exhibit a short characteristic path length and a 
short network diameter (the maximum distance between any two nodes), which 
suggests their coupling as single modules. To assess the viral levels of local 
clustering, we generated random networks of the same size and degree distribution. 
Our results show that the level of local clustering is low in KSHV, in fact comparable 
to equivalent random networks, and thus the KSHV network cannot be classified as 
small-world. In contrast, all known cellular protein interaction networks are 
unambiguously small-world, even after the effect on local clustering due to degree 
distribution and network size, is filtered out.  
In S.cerevisiae, Maslov and Sneppen demonstrated the existence of a degree 
correlation by showing that hubs tend to avoid each other while preferring low-
connectivity nodes (Maslov and Sneppen, 2002). As a result, the yeast network has 
well-separated modules, and errors in one module do not easily propagate to other 
modules. In the viral networks, there is no such declining degree correlation and 
hubs do not tend to avoid each other, which offers additional evidence that these viral 
networks could be viewed as single, highly coupled modules. As a consequence of 
these unusual topological features, viral networks are more resistant to deliberate 
attacks than other networks, as both network size and characteristic path length 
remain more stable after the most highly connected nodes are removed. 
 
 
Figure 27: Simulations of deliberate attack on KSHV and yeast networks by removing their 
most highly connected nodes. 
After each node is removed, the new network characteristic path length (average distance between 
any two nodes) and size (number of nodes) of the remaining single largest connected component 
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(SLCC) are computed and plotted as a multiple or fraction of the original parameters. KSHV exhibits 
much higher attack tolerance, as the increase in path length and the decrease in network size are 
considerably smaller.  
5.5  Relationship between protein interaction and expression 
profile. 
Since the KSHV interactome constitutes the first substantial viral protein interaction 
dataset on which statistical analysis is possible and in order to get hints on the extent 
to which global network properties and “super-global” host effect manifest themselves 
on the local level, we examined the relationship between protein interaction, 
sequence conservation, expression profile and function in detail. As protein 
interactions have been shown to be powerful predictors of protein function, we 
assigned all KSHV proteins into 5 functional classes and analysed which classes 
preferentially interact with each other (Samanta and Liang, 2003). Only proteins 
belonging to the “gene regulation” class interacted with proteins of the same class in 
a statistically significant way, whereas most proteins interacted with proteins of other 
functional classes, suggesting that many proteins have additional, yet still unknown 
functions. Interactions between proteins in the “host interaction” class are highly 
suppressed, probably reflecting missing virus-host interactions.  
The 15 viral hubs with >5 interaction partners represent all functional classes and 
include three proteins Orf23, Orf28 and Orf31 with unknown function. Since viral hubs 
tend to be conserved across herpesviral subfamilies, they are potential targets for 
drug design. The combined analysis of expression profile and local network topology 
gives hints which viral hubs are involved rather in static or dynamic complexes. 
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Figure 28: Correlation between viral protein interactions and expression profile. 
Interacting proteins share more similar expression profiles. All pairwise expression profile correlations 
determined based on results by Jenner et al. were plotted in a matrix for 81 KSHV ORFs (Jenner et 
al., 2001). Interacting protein pairs are indicated as circles. Standard Pearson correlation of two 
vectors was used to compute the expression profile correlation of any two KSHV ORFs. The average 
expression correlation [AEC] for random pairs of ORFs was determined to be 0.804 for random pairs 
and 0.839 for interacting pairs [p=0.0004]. 
 
 
Figure 29: Dynamic vs. static interactions of viral hubs. 
The correlation between AEC and the clustering coefficient C proposes either static or dynamic 
interactions for viral hubs. The size of the circles indicates the number of interaction partners, the 
colours refer to the functional class. If interactions are static as in a large complex, proteins are more 
likely to interact with each other (hence high C) and to be expressed at the same time as their 
interaction partners (hence high AEC). On the other hand, if interactions take place at different time or 
place, both C and AEC should be lower. In contrast to previous studies on party versus date hubs 
which used raw c values, we evaluated clustering based on its significance (p-value adjusted), which 
enabled us to use the smaller virus datasets, and filtered out the effect on clustering due to the 
underlying degree distribution, which was shown to be considerable. For example, the Orf9 
polymerase and the Orf41 helicase, which are both involved in replication and most likely form a 
stable complex, are both high in C and AEC values, whereas the ORF 36 kinase possesses low C and 
AEC values as anticipated for an enzyme. This analysis implies that K10, one of the major KSHV 
hubs, probably participates in a stable complex. 
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5.6  Creating an interplay between viral and human protein 
networks 
The network analyses of the KSHV and VZV interactomes revealed unique features 
of viral systems which also manifested themselves on the local level. Since we 
hypothesized that many of them could be attributed to missing virus-host interactions, 
we modeled the interplay between viral and human protein networks. As there is not 
sufficient experimental interaction data for the human proteome available, we used a 
prototypical human protein interaction network derived from high-confidence 
interactions in S. cerevisiae, C. elegans and D. melanogaster (Lehner and Fraser, 
2004) Since hardly any published human proteins targeted by KSHV lie within this 
host network, we connected the viral and host networks by predicting interactions 
between KSHV and human proteins if both proteins have orthologs in a third 
organism which are known to interact. 
Table 5 Previously published KSHV-human interactions 
PubMed ID KSHV protein Human protein (Ensembl Gene ID) 
12584338* gB(ORF8) alpha3integrin(ENSG00000005884) 
12584338* gB(ORF8) beta1integrin(ENSG00000150093) 
11752170* K15(ORFK15) HAX-1(ENSG00000143575) 
12388711* K7(ORFK7) CAML(ENSG00000164615) 
11336706* kaposinA(ORFK12) cytohesin-1(ENSG00000108669) 
11038375* LANA-1 (ORF73) ATF4/CREB2(ENSG00000128272) 
11425857* LANA-1 (ORF73) CBP(ENSG00000005339) 
11000236* LANA-1 (ORF73) CIR(***) 
12829841* LANA-1 (ORF73) Gsk-3A(ENSG00000105723) 
12829841* LANA-1 (ORF73) Gsk-3B(ENSG00000082701) 
10562490* LANA-1 (ORF73) HistoneH1(ENSG00000189060) 
12486118* LANA-1 (ORF73) HP1-alpha(ENSG00000094916) 
12941895* LANA-1 (ORF73) KLIP1(***) 
11000236* LANA-1 (ORF73) mSin3A(ENSG00000169375) 
12768028* LANA-1 (ORF73) p53(ENSG00000141510) 
10559289* LANA-1 (ORF73) RING3(ENSG00000112526) 
11000236* LANA-1 (ORF73) SAP30(ENSG00000164105) 
12477864* Rap (ORFK8) C/EBPalpha(***) 
12885907* Rap (ORFK8) C/EBPalpha(***) 
11533213* Rap (ORFK8) CBP(ENSG00000005339) 
12915577* Rap (ORFK8) Cdk2(ENSG00000123374) 
12604819* Rap (ORFK8) hSNF5(ENSG00000099956) 
12885907* Rap (ORFK8) p21(ENSG00000124762) 
11090200* Rap (ORFK8) p53(ENSG00000141510) 
12612078* RTA (ORF50) Brg1(ENSG00000127616) 
12477864* RTA (ORF50) C/EBPalpha(***) 
11160690* RTA (ORF50) CBP(ENSG00000005339) 
11390631* RTA (ORF50) CBP(ENSG00000005339) 
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12612078* RTA (ORF50) CBP(ENSG00000005339) 
11160690* RTA (ORF50) c-Jun(ENSG00000177606) 
11160690* RTA (ORF50) HDAC-1(ENSG00000116478) 
11711586* RTA (ORF50) MGC2663(ENSG00000130818) 
12832621* RTA (ORF50) RBP-Jkappa(ENSG00000168214) 
11741976* RTA (ORF50) STAT3(ENSG00000168610) 
12612078* RTA (ORF50) TRAP230(ENSG00000184634) 
9829980* vBcl-2(ORF16) DIVA(ENSG00000137875) 
12890756* vFLIP(ORFK13) IKK-gamma(ENSG00000073009) 
11027294* vIRF-1 (ORFK9) p300(ENSG00000100393) 
11390621* vIRF-1 (ORFK9) p53(ENSG00000141510) 
10438822* vIRF-1 (ORFK9) ICSBP(ENSG00000140968) 
10438822* vIRF-1 (ORFK9) IRF1(ENSG00000125347) 
10438822* vIRF-1 (ORFK9) p300(ENSG00000100393) 
10200596* VIRF-2(ORFK11) ICSBP(ENSG00000140968) 
10200596* VIRF-2(ORFK11) IRF-1(ENSG00000125347) 
10200596* VIRF-2(ORFK11) IRF-1(ENSG00000125347) 
10200596* VIRF-2(ORFK11) IRF-2(ENSG00000168310) 
10200596* VIRF-2(ORFK11) p300(ENSG00000100393) 
10200596* VIRF-2(ORFK11) RelA/p65(ENSG00000173039) 
10200596* VIRF-2(ORFK11) RelA/p65(ENSG00000173039) 
10666184* vMIP-3(ORFK4.1) CCR4(ENSG00000183813) 
10377196* vMIP-I(ORFK6) CCR8(ENSG00000179934) 
10736178* vMIP-II(ORFK4) CCR5(ENSG00000188239) 
11700073* vMIP-II(ORFK4) CCR5(ENSG00000188239) 
10736178* vMIP-II(ORFK4) CXCR4(ENSG00000121966) 
10200596* VIRF-2(ORFK11) ICSBP(ENSG00000140968) 
10200596* VIRF-2(ORFK11) IRF-1(ENSG00000125347) 
10200596* VIRF-2(ORFK11) ICSBP(ENSG00000140968) 
* PubMed ID of reference article 
*** Unable to be mapped to a unique ENSEMBL gene ID 
 
By this approach, we received 20 high-confidence interactions between 8 KSHV and 
20 human proteins which are interconnected within the human network. Nineteen of 
these 20 virus-host interactions were tested by CoIP and a surprisingly large 
percentage (13/19 or 68.4%) could be confirmed (Table 6). 
While published viral-host interactions tend to involve genes or interactions specific to 
human or higher eukaryotes (since most human targets have no orthologs or 
orthologous interactions in the three lower-eukaryotic model organisms), the 
predicted viral-host interactions involve genes and interactions common from lower 
eukaryotes to human and hence might reflect more general host-interacting 
mechanisms. 
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Table 6 Predicted and verified virus-host interactions. 
 viral  
protein 
cellular 
protein 
Y2H CoIP 
1. ORF2 SDF2 + + 
2. ORF9 DPD2 + + 
3. ORF18 121022 - + 
4. ORF18 ST5A - + 
5. ORF18 ST5B n.d. n.d. 
6. ORF18 RL4 - - 
7. ORF36 SERA - - 
8. ORF36 XPD - + 
9. ORF36 GFA2 + + 
10. ORF36 CHK1 - + 
11. ORF36 LSM1 - - 
12. ORF46 PCNA - + 
13. ORF60 U84B - + 
14. ORF60 105011 + + 
15. ORF60 149100 - + 
16. ORF60 RIR2 - - 
17. ORF61 RIR1 - + 
18. ORF72 CDK6 - + 
19. ORF72 CDK3 + - 
20. ORF72 CKS2 - - 
 confirmed interactions
(percentage) 
5/19  
(26.3%)
13/19  
(68.4%) 
 
Using the predicted KSHV-human interactions, we were able to dock the two 
interactomes at each other (Figure 30). Strikingly, the topology of the KSHV network 
changes completely from a highly coupled module to a more typical scale-free 
network once it is connected to its host. To rigorously assess the impact of the two 
systems upon each other, we carried out a combined viral-host network analysis, one 
level at a time (Figure 31). Starting with the KSHV network (level 0), we first added in 
their direct human targets together with the interactions they carry (level 1), 
subsequently we added in those human targets’ own interactions partners and their 
interactions (level 2), and so on, until the viral network is completely assimilated into 
the host network. 
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Figure 30: Global view of the interplay between the KSHV and a predicted high-confidence 
human interaction network. 
The network consists of 10,636 edges among 3,169 nodes. Viral proteins are depicted as red nodes, 
cellular interacting proteins (level 1 and 2) as blue nodes and cellular proteins (level >2) as grey 
nodes. Interactions between viral proteins are depicted as red edges, between viral and cellular 
proteins as green edges and between cellular level 1 and 2 proteins as blue edges. 
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Figure 31: Local view of the combined viral and host interaction networks (level ≤ 2). 
 
To evaluate the topology of the combined virus-host network, we reasoned that a 
correctly combined system should be able to distinguish itself from randomly 
combined networks. To generate an ensemble of equivalent random viral-host 
networks, we adopted and compared two separate simulation strategies. Whereas in 
the first approach human targets were assigned randomly, in the second, even more 
stringent approach, orthology relationships between KSHV and third organism 
proteins were randomly shuffled and the whole procedure used to predict KSHV-
human interactions was repeated to produce simulated “predictions” (Figure 32).  
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Figure 32: Power coefficient γ of the combined viral-host interaction network at each level.  
Power coefficient γ of the combined viral-host interaction network at each level. KSHV together with 
their direct human targets constitute the viral-host network at level 1, the level 1 network together with 
their own interaction partners constitute the viral-host network at level 2, and so on. The red and the 
blue lines indicate the power coefficient of the isolated KSHV and human network, respectively. The 
green line connects the power coefficient γ at each level of the true viral-host network, while the 
boxplots show the distribution of γ at each level of 100 simulated viral-host networks.  
 
As the level elevates, the viral-host system exhibits an increasing power coefficient 
indicating that the KSHV network more and more assimilates to the human network. 
At each level, simulated viral-host systems tend to have smaller power coefficients 
than the correctly assembled networks, with the most significant distinction at level 2 
(empirical p-value < 0.01). Thus, at the level carrying most biological relevance 
(KSHV’s human targets and their own interaction partners in turn) and suffering from 
minimal noise (level 3 already includes a sizable fraction of the human network and 
many of the interactions are conceivably no longer relevant to the viral-host context), 
the combined virus-host network significantly assimilates human network properties. 
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While we have shown that virus and host interactomes possess a distinct network 
topology, their interplay may lead to emergent new system properties representing 
specific features of the viral pathogenesis. Obviously, numerous biological 
hypotheses resulting from our study remain to be investigated in detail. The 
availability of protein interaction networks in other herpesviruses and large-scale 
virus-host interaction data in the near future will boost our knowledge on the function 
of many still poorly characterised viral proteins and the phylogeny of herpesviruses. It 
will eventually lead to a considerably improved understanding of viral pathogenesis 
and evoke novel therapeutic strategies. 
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fig. figure 
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H. pylori Heliobacter pylori 
HA hemagglutinin 
HAART highly active antiretroviral threapy 
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